 IMMUNOGENIC COMPOSITIONS
专利摘要:
The present invention provides conjugates comprising capsular polysaccharide fragments of group B streptococcus (GBS) type III. Suitable fragments can be produced by synthesis or depolymerization of the native polysaccharide. 公开号:BE1024634B1 申请号:E2017/5163 申请日:2017-03-16 公开日:2018-05-14 发明作者:Roberto Adamo；Francesco Berti；Filippo Carboni；Y Ros Immaculada Margarit 申请人:Gsk Vaccines S.R.L.； IPC主号:
专利说明:
(30) Priority data: 04/05/2016 EP 16020113.3 (73) Holder (s): GSK Vaccines S.R.L. 53100, SIENA Italy (72) Inventor (s): ADAMO Roberto 53100 SIENA Italy BERTI Francesco 53100 SIENA Italy CARBONI Filippo 53100 SIENA Italy MARGARIT Y ROS Immaculada 53100 SIENA Italy (54) IMMUNOGENIC COMPOSITIONS (57) The present invention relates to conjugates comprising fragments of the capsular polysaccharide of group B streptococcus (GBS) from 0 / ^ 1/4 to PI H Ί type III. Suitable fragments can be P ”v3ar Jp produced by synthesis or by depolymerization of the native polysaccharide. [f ^ .ß-GicNAc f ß-Gal t a-HeuHÂc FIG. 1 BELGIAN INVENTION PATENT FPS Economy, SMEs, Middle Classes & Energy Publication number: 1024634 Deposit number: BE2017 / 5163 Intellectual Property Office International Classification: A61K 47/64 Date of issue: 05/14/2018 The Minister of the Economy, Having regard to the Paris Convention of March 20, 1883 for the Protection of Industrial Property; Considering the law of March 28, 1984 on patents for invention, article 22, for patent applications introduced before September 22, 2014; Considering Title 1 “Patents for invention” of Book XI of the Code of Economic Law, article XI.24, for patent applications introduced from September 22, 2014; Having regard to the Royal Decree of 2 December 1986 relating to the request, the issue and the maintenance in force of invention patents, article 28; Considering the patent application received by the Intellectual Property Office on 16/03/2017. Whereas for patent applications falling within the scope of Title 1, Book XI of the Code of Economic Law (hereinafter CDE), in accordance with article XI. 19, §4, paragraph 2, of the CDE, if the patent application has been the subject of a search report mentioning a lack of unity of invention within the meaning of §ler of article XI.19 cited above and in the event that the applicant does not limit or file a divisional application in accordance with the results of the search report, the granted patent will be limited to the claims for which the search report has been drawn up. Stopped : First article. - It is issued to GSK Vaccines S.R.L., Via Fiorentina 1, 53100 SIENA Italy; represented by PRONOVEM - Office Van Malderen, Avenue Josse Goffin 158, 1082, BRUXELLES; a Belgian invention patent with a duration of 20 years, subject to payment of the annual fees referred to in article XI.48, §1 of the Code of Economic Law, for: IMMUNOGENIC COMPOSITIONS. INVENTOR (S): ADAMO Roberto, c / o GSK Vaccines S.R.L., Via Fiorentina 1, 53100, SIENA; BERTI Francesco, c / o GSK Vaccines S.R.L., Via Fiorentina 1, 53100, SIENA; CARBONI Filippo, c / o GSK Vaccines S.R.L., Via Fiorentina 1, 53100, SIENA; MARGARIT Y ROS Immaculada, c / o GSK Vaccines S.R.L., Via Fiorentina 1, 53100, SIENA; PRIORITY (S): 04/05/2016 EP 16020113.3; DIVISION: divided from the basic application: filing date of the basic application: Article 2. - This patent is granted without prior examination of the patentability of the invention, without guarantee of the merit of the invention or of the accuracy of the description thereof and at the risk and peril of the applicant (s) ( s). Brussels, 05/14/2018, By special delegation: BE2017 / 5163 IMMUNOGENIC COMPOSITIONS Technical area The present invention relates to conjugates comprising fragments of the group B streptococcus (GBS) capsular polysaccharide of serotype III. The conjugates comprising the fragments confer higher immunoprotection rates than those triggered by conjugates comprising the native polysaccharide. Suitable fragments can be produced by synthesis or by depolymerization of the native polysaccharide. Context Streptococcus agalactiae (also known as "group B streptococcus" or "GBS") is an β-hemolytic, gram-positive, encapsulated microorganism that colonizes the anogenital system of 25-30% of healthy women. It is the main cause of sepsis and neonatal meningitis, especially in infants born to mothers who are carriers of the bacteria. The pathogen can also affect adults with underlying disease, especially the elderly. In susceptible individuals, such as the elderly, children and immunocompromised individuals, the bacteria can become pathogenic and cause a disease such as meningitis or septicemia. GBS capsule is a major virulence factor allowing the bacteria to escape the defenses BE2017 / 5163 human innate immune systems. It consists of repetitive high molecular weight (UR) polymers of vaccines,, 'antigens made up of multiple identical units of four to seven monosaccharides. GBS can be classified into ten serotypes (la, lb, II, III, IV, V, VI, VII, VIII, and IX) differing in the chemical composition and the profile of glycosidic bonds of their repeating units of the capsular polysaccharide. GBS capsular saccharides are being studied for use in However, saccharides are independent and are generally weakly immunogenic. Conjugation to a carrier can convert T-independent antigens to T-dependent antigens, thereby enhancing memory responses and allowing the development of protective immunity. Therefore, the most effective saccharide vaccines are based on glycoconjugates. Much work on GBS capsular polysaccharide vaccines has been done by Dennis Kasper and colleagues (see, for example, references Paoletti et al. (1990), J. Biol. Chem 265: 18278-83 ; (1990) J Clin Invest 86: 1428-33; Wessels et al Paoletti et al. (1992) Infect Immun 60: 400914; Paoletti BE2017 / 5163 et al ., (1992) J Clin Invest 89: 203-9; Wessels and al. (1987 ) Proc Natl Acad Sci USA 84: 9170-4 ; Wang and al. (2003 ) Vaccine 21 : 1112-7; Wessels et al . (1993) Infect Immune 61: 4760 -6 ; Wessels et al. (1995 ) J Infect Say 171: 879-84. He was shown that vaccines conjugates for each of GBS serotypes la, lb, II, III, and V are safe and immunogenic in humans. However, there remains a need to develop other improved GBS vaccines. summary The applicants have discovered that conjugates comprising certain fragments of the capsular polysaccharide of group B streptococcus of serotype III can trigger higher antibody titers than the conjugates comprising the native capsular polysaccharide. Thus, in a first aspect of the invention, there is provided a conjugate comprising a fragment of a GBS capsular polysaccharide of serotype III is a carrier protein in which the fragment and an oligosaccharide comprising from 2 to 15 repeating units. In particular, the conjugate has a degree of glycosylation from 2 to 20. In one embodiment, the oligosaccharide is a synthetic oligosaccharide. In another embodiment, the oligosaccharide is prepared by depolymerization of the PSC of GBS. In particular, the oligosaccharide comprises from 2 to 11 repeating units. Even more particularly, the oligosaccharide comprises from 3 to 9 repeating units. BE2017 / 5163 In particular, the support protein is chosen from the group consisting of diphtheria toxoid, CRM197 and tetanus toxoid. In a second aspect of the invention, there is provided a composition comprising the conjugate of the first aspect and a pharmaceutically acceptable carrier. In particular, the composition is an immunogenic composition. Even more particularly, the composition is a vaccine composition. In a third aspect of the invention there is provided a method of treating a subject infected with group B streptococcus comprising administering to a subject a conjugate of the first aspect or the composition of the second aspect. In a fourth aspect of the invention there is provided a composition of the second aspect for use in a method of treating or preventing a disease. Brief description of the figures Figure 1 - The structure of the repeating unit of the GBS serotype III capsular polysaccharide (Gai = galactose, Glc = glucose, GlcNAc = N-acetylglucosamine, NeuNAc = N-acetylneuraminic acid (sialic acid). Figure 2 - HPLC chromatogram of the eluted oligosaccharides (depolymerized serotype III GBS capsular polysaccharides (DP)) with a different chain length, where DP2 indicates oligosaccharides comprising two repeating units, DP3 indicates oligosaccharides comprising 3 repeating units, etc. Figure 3 - NMR (400 MHz, D 2 O) of the GBS serotype III capsular polysaccharide material depolymerized against the full-length polysaccharide. Figure 4A - Provides the structure of the repeating unit of the GBS serotype III polysaccharide. BE2017 / 5163 Figure 4B - Provides the structure of fragment 1 of linear pentasaccharide DPI (compound D. Figure 4C - Provides the structure of fragment 2 of branched pentasaccharide DPI (compound 2 ). Figure 4D - Provides the structure of fragment 3 of synthetic 2 synthetic 3 pentasaccharide Y-shaped DPI (compound 3). Figure 5 - Diagram of the synthesis of synthetic fragment 1 (compound 1). Figure 6 - Synthesis of the fragment (compound 2). Figure 7 - Synthesis of the fragment (compound 3). Figures 8A-B - MALDI TOF spectra of conjugated oligosaccharides. Figure 9A - Competitive ELISA experiments showing a length-dependent capacity of the oligosaccharides to inhibit the binding of an antiPSIII mAb to the native PSIII. Figure 9B - Competition by RPS of the binding of native PSIII to Fab by oligosaccharides. Figure 10 - ELISA titers of anti-PSIII measured in sera of mice immunized with GBS59-PSIII (5 pg) using conjugates of CRM197 from three synthetic fragments as sensitization reagents. BE2017 / 5163 Figures 11A-B - Titers of anti-PSIII (11A) and OPKA (11B) in the sera of mice immunized with glycoconjugates of oligosaccharides. Figure 12A - Effect of the saccharide / protein ratio in DP 2 and 3 conjugates measured by an ELISA test. The diagram shows the calculation of the P value (Mann-Whitney test). The values in parentheses represent the saccharide / protein molar ratio (degree of glycosylation). Figure 12B - Effect of the saccharide / protein ratio in DP 2 and 3 conjugates measured by OPKA. The values in parentheses represent the saccharide / protein molar ratio (degree of glycosylation). specific GBS from four to and one or detailed description The chemical structures of capsular polysaccharides (PSC) serotypes la, lb, II, III, IV, V, VI, VII, VIII and IX are well described in the literature. They are composed of repeating units of seven monosaccharides with a skeleton two side chains. A repeating unit (UR) is the part of the capsular polysaccharide whose repetition by bonding the repeating units together successively produces the complete polysaccharide. The PSC of GBS serotype III (also called PSIII here) has a skeleton of repeating units of the trisaccharide [^ 6) -β-DN-acetyl-glucosamine- (1 ^ 3) -ß-Dgalactose- (1 ^ 4) -ß-D-glucose- (1 ^]. Each repeating unit carries a disaccharide side chain of DNA-acetylneuraminic acid- (2 ^ 3) -ß-D-galactose, BE2017 / 5163 linked in 1 ^ 4 via galactose to the sguelette of N-acetyl-glucosamine (Figure 1). While certain fragments of the GBS polysaccharide of serotype III are known in the art, the inventors have discovered a specific population or a subset of fragments having an enhanced immunogenicity compared to other fragments or to the full-length capsular polysaccharide, by example. Generally, the term "polysaccharide" (PS) refers to a saccharide having from about 50 to about 2000 or more repeating units. The term “fragment” refers to a part of the capsular polysaccharide, particularly an “oligosaccharide” comprising from approximately 2 to approximately 20 repeating units, particularly from 2 to 15 repeating units, even more particularly from 2 to 11 repeating units, 2 to 9 repeating units, 2 to 7 repeating units, 3 to 7 repeating units, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 repeating units. The term "derivative" as used herein refers generally to any structurally related molecule having the same scaffold as the repeating unit but which is modified by the addition, deletion or substitution of one or more groups functional. For example, a derivative of the repeating unit may include replacement of one or more of the hydroxyl groups with a different functional group or by the addition of a substituent such as a linker group. In certain embodiments, the reduction of the aldehyde group of the SGB III oligosaccharides can be obtained by treatment with NaBH 4 to produce a repetitive modified structure having the following unit: BE2017 / 5163 In other repetitive modified embodiments, has the following structure a unit Preparation of oligosaccharides The capsular saccharides can be purified by known techniques, as described, for example, in Wessels et al. (1990) J. Clin. Invest. 86: 1428-33 and Wessels et al. (1989) Infect Immun 57: 108994. A typical process involves base extraction, centrifugation, filtration, RNase / DNase treatment, protease treatment, concentration, exclusion chromatography, ultrafiltration, anion exchange chromatography, and another ultrafiltration. Cell processing BE2017 / 5163 of GBS with the enzyme mutanolysin, which cleaves the wall of the bacterial cell to release the components of the bacterial wall, is also useful. As a variant, the purification method described in document WO 2006/082527 can be used. This involves base extraction, ethanol / CaCA treatment, precipitation with CTAB, and resolubilization. Another variant of the method is described in document WO 2009/081276. The oligosaccharides of the invention are shorter than the native capsular polysaccharide, and they can be chemically modified. The full length polysaccharides can be depolymerized to give shorter fragments for use with the invention, for example, by hydrolysis in a mild acid, by heating, by exclusion chromatography, etc. In particular, the capsular polysaccharide of serotype III used in the invention can be depolymerized as described in Michon et al. (2006) Clin. Immunol vaccine. August 2006; 13 (8): 936-43. This document describes the partial depolymerization of capsular saccharides of serotype III by cleavage with gentle deamination into antigenic fragments comprising 2,5-anhydro-D-mannose reducing terminal residues. In short, the capsular saccharide is dissolved in 0.5 N NaOH and heated to 70 ° C for a period between 1 and 4 h. The length of this incubation controls the degree of depolymerization, which can be determined by conventional methods (e.g., by HPLC as described in WO 96/40795). The sample is placed in an ice-water bath before BE2017 / 5163 the addition of glacial acetic acid to bring the pH to 4. The partially N-deacylated product is then deaminated by the addition of 5% NaNCq (w / v) with stirring at 4 ° C for 2 h. The free aldehydes of the newly formed 2,5-anhydro-D-mannose residues can be used for conjugation to a carrier protein. Depolymerization of the capsular saccharide of serotype III has been reported by endo-βgalactosidase (Paoletti et al. 1990 J. Biol. Chem. 265: 18278-83; Paoletti et al. (1992) J Clin Invest 89: 2039; Wessels et al. (1987) Proc Natl Acad Sci USA 84: 9170-4; Wang et al. (2003) Vaccine 21: 1112-7) including the use of depolymerized material to form conjugates with a tetanus toxoid carrier . Ozonolysis of capsular polysaccharides from GBS serotypes III and VIII has also been used for depolymerization (US 6,027,733 and US 6,274,144). However, the invention is not limited to oligosaccharides purified from natural sources, and the saccharides can be obtained by other methods, such as total or partial synthesis. In certain embodiments, the oligosaccharide comprises at least one linker for conjugation to a support protein. In other embodiments, the oligosaccharide comprises at least one repeating unit modified for conjugation to a carrier protein. BE2017 / 5163 Conjugation of oligosaccharides In general, a covalent conjugation of the oligosaccharides to supports amplifies the immunogenicity of the oligosaccharides because it converts them from T-independent antigens into T-dependent antigens, thus allowing the priming of the immunological memory. The term "conjugate" refers to an oligosaccharide covalently linked to a support protein. In some embodiments, an oligosaccharide is linked directly to a support protein. In other embodiments, an oligosaccharide is indirectly linked to a protein via a spacer or linker. As used herein, the term "linked directly" means that the two entities are linked by a chemical bond, preferably a covalent bond. As used herein, the term "indirectly linked" means that the two entities are linked by a linking radical (as opposed to a direct covalent bond). In some embodiments, the linker is the dihydrazide of adipic acid. In other embodiments, the linker is a derivative of a repeating unit. Representative conjugates according to the present invention include those formed by joining the oligosaccharide together with the carrier protein. The covalent bond of oligosaccharides to proteins is known in the art and is generally obtained by targeting amines of lysines, carboxylic groups of aspartic / glutamic acids or sulfhydryls of cysteines. For example, cyanate esters formed randomly from BE2017 / 5163 hydroxyls of sugars can be reacted with lysines of the protein or hydrazine of a spacer which are then condensed to carboxylic acids of the carrier protein via carbodiimide chemistry. Alternatively, the aldehydes produced by the random oxidation of periodate can either be used directly for a reductive amination on the amines of the support protein, or converted to amines following the insertion of a spacer allowing the step of conjugation to the protein via the formation of thioester or amide bonds. Another strategy employs partial hydrolysis of the purified oligosaccharide and subsequent fractionation to select the population of fragments having a defined average size. A primary amino group can then be introduced at the reducing ends of the oligosaccharide to be used ultimately for the insertion of either a diester or a bifunctional linker for conjugation to the protein. The term "carrier protein" refers to a protein to which the oligosaccharide is coupled or attached or conjugated, generally for the purpose of enhancing or facilitating the detection of the antigen by the immune system. Oligosaccharides are independent antigens which are weakly immunogenic and do not lead to long-term immunoprotective responses. The conjugation of the oligosaccharide antigen to a support protein changes the context in which effector immune cells respond to oligosaccharides. The term carrier protein is intended to cover both small and large peptides BE2017 / 5163 polypeptides (> 10 kDa). The carrier protein can include one or more helper T cell epitopes. Useful carrier proteins include toxins or bacterial toxins, such as diphtheria toxoid or tetanus toxoid. Fragments of toxins or toxoids can also be used, for example, fragment C of tetanus toxoid (reference 8). The mutant CRMxgv of the diphtheria toxin (references 9 to 11) is particularly useful with the invention. Other suitable support proteins include the outer membrane protein of N. meningitidis (reference 12), synthetic peptides (references 13 and 14), heat shock proteins (references 15 and 16), pertussis proteins (references 17 and 18), cytokines (reference 19), lymphokines (reference 19), hormones (reference 19), growth factors (reference 19), human serum albumin (preferably recombinant), artificial proteins comprising multiple epitopes of human CD4 + T lymphocytes originating from various antigens derived from pathogens (reference 20) such as N19 (reference 21), protein D of H. influenzae (references 22 and 23), the pneumococcal surface protein PspA (reference 24), pneumolysin (reference 25), iron capture proteins (reference 26), toxin A or B from C. difficile (reference 27), recombinant exoprotein A from Pseudomonas aeruginosa (rEPA) (reference 28), GBS protein, etc. a BE2017 / 5163 Particularly suitable carrier proteins include CRM197, tetanus toxoid (TT), fragment C of tetanus toxoid, protein D, non-toxic mutants of tetanus toxin and diphtheria toxoid (DT). Other suitable support proteins include the protein antigens GBS80, GBS67 and GBS59 of Streptococcus agalactiae and fusion proteins, for example, GBS59 (6xD3) disclosed in WO 2011/121576 and GBS59 (6xD3) -1523 disclosed in document EP 14179945.2. The use of such GBS protein antigens may be advantageous for a GBS vaccine because, unlike heterologous carriers like CRM197, the protein has a dual role in increasing the immunogenicity of the oligosaccharide while also causing an immunoprotective response. Therefore, the immune response elicited against the carrier can provide an additional protective immune response against GBS, particularly against a protein of GBS. As used herein, the term "degree of glycosylation" refers to the number of oligosaccharides per molecule of carrier protein and is calculated based on the concentration of protein and carbohydrate. It has been found that loading between 2 and 9 oligosaccharides per molecule of carrier protein is optimal. It should be understood that such loading values, and thus the degree of glycosylation, are mean values reflecting all of the conjugates in the sample. Alternatively, the degree of glycosylation BE2017 / 5163 can be described with reference to the oligosaccharide / protein ratio (w / w). For example, a ratio between 1/5 (i.e., excess protein) and 10/1 (i.e., an excess of oligosaccharide). The compositions can comprise a small amount of free support (reference 29). When a given carrier protein is present in both free and conjugated form in a composition of the invention, the unconjugated form is preferably not more than 5% of the total amount of the carrier protein in the composition as a whole, and more preferably present at less than 2% by weight. After conjugation, the free and conjugated oligosaccharides can be separated. There are many suitable methods, including hydrophobic chromatography, tangential ultrafiltration, diafiltration, etc. (see also references 30 and 31, etc.). A preferred method is described in reference 32. In particular, the conjugates of the invention will have the general formula: ([UR] mOX) n2 -P In which UR represents the repeating unit of PS III of GBS, l <nl <12, Kn2 <20, P represents a support protein. Immunogenic compositions The invention further provides an immunogenic composition comprising a conjugate which comprises at least BE2017 / 5163 an oligosaccharide conjugated to a support protein. The immunogenic compositions can comprise any appropriate quantity of oligosaccharide (s) per unit dose. The appropriate amounts of oligosaccharide (s) can be 0.1 to 50 µg per unit dose. Generally, each oligosaccharide is present in an amount of 1 to 30 pg, for example, from 2 to 25 pg, and in particular from 5 to 20 pg. The methods of administering the immunogenic compositions of the invention are discussed below. In short, the immunogenic compositions of the invention can be administered in single or multiple doses. The inventors have discovered that administration of a single dose of the immunogenic compositions of the invention is effective. Alternatively, a unit dose followed by a second unit dose may be effective. Generally, the second (or third, fourth, fifth, etc.) unit dose is identical to the first unit dose. The second unit dose can be administered at any appropriate time after the first unit dose, especially after 1, 2 or 3 months. Generally, the immunogenic compositions of the invention will be administered intramuscularly, for example, by intramuscular administration into the thigh or upper arm as described below. The immunogenic compositions of the invention may include one or more adjuvants. However, the use of non-adjuvanted compositions is also envisaged, for example, it may be advantageous to omit the adjuvants in order to reduce the potential toxicity. Therefore, immunogenic compositions which contain no adjuvant or which do not contain any adjuvant based on aluminum salt are contemplated. BE2017 / 5163 Combinations of Conjugates and Other Antigens The immunogenic compositions of the invention may include one or more other antigens. The other antigen (s) may include other conjugates comprising oligosaccharides derived from GBS capsular polysaccharides. Different GBS conjugates can include different types of conjugates from the same GBS serotype and / or conjugates from different GBS serotypes. The generally produced by composrtron will generally be produced by the preparation of the separate conjugates (for example, a different conjugate for each serotype) and then the combination of the conjugates. The other antigen (s) may include protein antigens from GBS. The other antigen (s) may include antigens from non-GBS pathogens. Thus, the compositions of the invention may further comprise one or more non-GBS antigens, including additional bacterial, viral or parasitic antigens. These can be chosen from the following: - a protein antigen of N. meningitidis from serogroup B, such as those in references 33 to 39, with the protein '287' (see below) and its derivatives (for example, 'AG287') being particularly preferred; BE2017 / 5163 a preparation of vesicles of the outer membrane (OMV) of N. meningitidis from serogroup B, such as those disclosed in references 40 to 43, etc. ; - a saccharide antigen of N. meningitidis of serogroup A, C, W135 and / or Y, such as the oligosaccharide disclosed in reference 44 from serogroup C or the oligosaccharides of reference 45; - a saccharide antigen of Streptococcus pneumoniae (for example, references 46 to 48, chapters 22 and 23 of reference 55); a hepatitis A virus antigen, such as an inactivated virus (for example, references 49 and 50, chapter 15 of reference 55); - a hepatitis B virus antigen, such as surface and / or core antigens (for example, references 50, 51, chapter 16 of reference 55); - a hepatitis C virus antigen (for example, reference 52); - a Bordetella pertussis antigen, such as pertussis holotoxin (PT) and filamentous hemagglutinin (FHA) from B. pertussis, possibly also in combination with pertactin and / or agglutinogens 2 and 3 (for example, references 53 and 54, chapter 21 of reference 55); - a diphtheria antigen, such as the diphtheria toxoid, for example (by reference 55); - a tetanus antigen, chapter 13 of such as tetanus toxoid (for example, chapter 25 of reference 55); BE2017 / 5163 - a saccharide antigen of Haemophilus influenzae B (Hib) (for example, chapter 14 of reference 55); - an antigen of N. gonorrhoeae (for example, references 33 to 35); - an antigen of Chlamydia pneumoniae (for example, references 56 to 62); - a Chlamydia trachomatis antigen (for example, reference 63); - a Porphyromonas gingivalis antigen (for example, reference 64); - one or more polio antigens [for example, references 65 and 66; reference 55 chapter 24) such as LPI; - one or more rabies antigens (for example, reference 67) such as the lyophilized inactivated virus (for example, reference 68, RABAVERT ™]; - measles, mumps and / or rubella antigens (for example, chapters 19, 20 and 26 of reference 55); - one or more influenza antigens (for example, chapters 17 and 18 of reference 55), such as the proteins of the hemagglutinin and / or neuraminidase surface; - an antigen of Moraxella catarrhalis (for example, reference 69); - a Streptococcus pyogenes antigen (group A streptococcus) (for example, references 70 to 72); - a Staphylococcus aureus antigen (for example, reference 73). BE2017 / 5163 When a saccharide or carbohydrate antigen is used, it is preferably conjugated to a support in order to amplify immunogenicity. The conjugation of H. influenzae B, meningococcal and pneumococcal saccharide antigens is well known. Toxic protein antigens can be detoxified when necessary (for example, detoxification of pertussis toxin by chemical and / or genetic means (see Reference 54)). When a diphtheria antigen is included in the composition, it is also preferred to include a tetanus antigen and pertussis antigens. Similarly, when a tetanus antigen is included, it is also preferred to include diphtheria and pertussis antigens. Similarly, when a pertussis antigen is included, it is also preferred to include diphtheria and tetanus antigens. The antigens can be absorbed on an aluminum salt. When there is more than one conjugate in a composition, not all of the conjugates need to be adsorbed. A preferred type of composition comprises other antigens which affect the elderly and / or the immunocompromised, and thus the GBS antigens of the invention can be combined with one or more antigens derived from the following non-GBS pathogens: influenza, Enterococcus faecalis, Staphylococcus aureus, Staphylococcus epidermis, Pseudomonas aeruginosa, Legionella pneumophila, Listeria monocytogenes, Neisseria meningitidis, and the parainfluenza virus. BE2017 / 5163 The antigens in the composition will generally be present at a concentration of at least pg / ml each. In general, the concentration of any given antigen will be sufficient to trigger an immune response against that antigen. In practical terms, there may be an upper limit to the number of antigens included in the compositions of the invention. The number of antigens (including GBS antigens) in a composition of the invention may be less than 20, less than 19, less than 18, less than 17, less than 16, less than 15, less than 14, less than 13, less than 12, less than 11, less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, less than 3, or less than 2. The number of GBS antigens in a composition of the invention may be less than 6, less than 5, less than 4, less than 3, or less than 2. Pharmaceutical processes and uses The immunogenic compositions of the invention may include acceptable. Acceptable "in addition to a pharmaceutically acceptable support" Typical pharmaceutical supports include any support which does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are generally large, slowly metabolized macromolecules such as proteins, polysaccharides, poly lactic acids, poly glycolic acids, polymeric amino acids, amino acid copolymers, sucrose (see, for example BE2017 / 5163 example, reference 74), trehalose (see, for example, reference 75), lactose, and lipid aggregates (such as oil droplets or liposomes). Such supports are well known to a person of average skill in the field. Vaccines can also contain diluents, such as water, saline, glycerol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present. The physiological saline phosphate sterile pyrogen-free phosphate buffer is a typical support. An in-depth discussion of pharmaceutically acceptable excipients is available by reference (see, for example, reference 76). The compositions of the invention can be in aqueous form (i.e., solutions or suspensions) or in a dried form (e.g. lyophilized). If a dried vaccine is used then it will be reconstituted in a liquid medium before injection. Lyophilization of conjugate vaccines is known in the art, for example, the product MENJUGATE ™ is presented in lyophilized form. When the immunogenic compositions of the invention comprise other conjugates, it is typical that the conjugates are prepared separately, mixed and then lyophilized. In this way, lyophilized compositions comprising two, three or four, etc. conjugates as described here can be prepared. To stabilize the conjugates during lyophilization, it may be preferred to include a sugar alcohol (for example, mannitol) and / or a disaccharide (for example, sucrose or BE2017 / 5163 trehalose), for example, in a concentration of 1 mg / ml and 30 mg / ml (for example, about 25 mg / ml) in the composition. The use of sucrose has been recommended as a stabilizer for GBS conjugate vaccines (see, for example, reference 77). However, it is typical that the stabilizer of the present invention is mannitol. When the dried vaccine is reconstituted in a liquid medium before injection, the concentration of residual mannitol will generally be about 2 to 20 mg / ml, for example, 3.75 mg / ml, 7.5 mg / ml or 15 mg / ml. The use of mannitol is advantageous because mannitol is chemically distinct from the monosaccharide repeating units of GBS capsular saccharides. This means that the detection of capsular saccharides, for example, for quality control analysis, can be based on the presence of repeating units of the saccharides without interference from mannitol. In contrast, a stabilizer such as sucrose contains glucose, which can interfere with the detection of repeating units of glucose in saccharides. The compositions can be presented in vials, or they can be presented in already filled syringes. Syringes can be supplied with or without a needle. A syringe will comprise a single dose of the composition, while a vial may comprise a single dose or multiple doses. The aqueous compositions of the invention are also suitable for reconstituting other vaccines from a lyophilized form. When a composition of the invention must BE2017 / 5163 be used for such an extemporaneous reconstitution, the invention provides a kit, which can comprise two vials, or can comprise an already filled syringe and a vial, with the contents of the syringe being used to reactivate the contents of the front vial injection. The compositions of the invention can be packaged in a unit dose form or in a multiple dose form. For multiple dose forms, vials are preferred over already filled syringes. Effective dosage volumes can be established routinely, but a typical human dose of the composition has a volume of 0.5 ml, for example, for intramuscular injection. The pH of the composition is preferably between 6 and 8, preferably about 7. A stable pH can be maintained by the use of a buffer. The immunogenic compositions of the invention generally include a potassium dihydrogen phosphate buffer. The potassium dihydrogen phosphate buffer can include about 1 to 10 mM potassium dihydrogen phosphate, for example, 1.25 mM, 2.5 mM or 5.0 mM. If a composition comprises an aluminum hydroxide salt, it is preferred to use a histidine buffer (see, for example, reference 78). The composition can be sterile and / or pyrogen-free. The compositions of the invention can be isotonic with respect to humans. The compositions of the invention are immunogenic, and are more preferably vaccine compositions. The vaccines according to the invention can be either prophylactic (that is to say, to prevent infection or disease) or therapeutic (that is, 25 BE2017 / 5163 say, to treat an infection or disease), but they will usually be prophylactic. The immunogenic compositions used as vaccines include an immunologically effective amount of antigen (s), as well as any other component, as required. By "immunologically effective amount" it is meant that the administration of this amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies according to the health and physical condition of the individual to be treated, age, the taxonomic group of the individual to be treated (for example, non-human primate, primate, etc.), the capacity of the immune system. of the individual to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the physician's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall within a relatively wide range which can be determined through routine testing. Within each dose, the amount of an individual saccharide antigen will generally be between 0.1 and 50 pg (measured by mass of saccharide), particularly between 1 and 50 pg or 0.5 to 25 pg, more particularly 2, 5 to 7.5 pg, for example, about 1 pg, about 2.5 pg, about 5 pg, about 10 pg, about 15 pg, about 20 pg or about 25 pg. Within each dose, the total amount of chimeric capsular saccharides will generally be <70 pg (measured by mass of saccharide), for example, <60 pg. In particular, the total amount can be <40 pg (for example, <30 pg) BE2017 / 5163 or <20 pg (for example, <15 pg). It may be advantageous to minimize the total amount of chimeric capsular saccharide (s) per unit dose in order to reduce potential toxicity. Therefore, a total amount <20 pg can be used, for example, <15 pg, <7.5 pg or <1.5 pg. GBS affects different areas of the body and thus the compositions of the invention can be prepared in various forms. For example, the compositions can be prepared in the form of injectables, in the form of either solutions or liquid suspensions. The composition can be prepared for pulmonary administration, for example, in the form of an inhaler, using a fine powder or a spray. The composition can be prepared in the form of a suppository or an ovum. The composition can be prepared for nasal, ear or eye administration, for example, in the form of a spray, drops, gel or powder (for example, references 79 and 80). Successful nasal administration of pneumococcal saccharides (references 81 and 82), Hib saccharides (reference 83), MenC saccharides (reference 84) and mixtures of Hib saccharide conjugates and MenC (reference 85) a been reported. The compositions of the invention may include an antimicrobial, particularly when packaged in multiple dose format. The compositions of the invention can comprise a detergent, for example, a TWEEN ™ (polysorbate), such BE2017 / 5163 than TWEEN ™ 80. Detergents are generally present at low rates, for example, <0.01%. The compositions of the invention may include sodium salts (e.g., sodium chloride) to give the tone. A concentration of 10 ± 2 mg / ml NaCl is typical. In some embodiments, a concentration of 4-10 mg / ml NaCl can be used, for example, 9.0, 7.0, 6.75 or 4.5 mg / ml. The compositions of the invention will generally include a tampon. A phosphate buffer is typical. The compositions of the invention can be administered in conjunction with other immunoregulatory agents. In particular, the compositions can comprise one or more adjuvants. Such adjuvants are known in the art and include, but are not limited to, aluminum salts such as alum and MF5 9. Processing procedures The invention also provides a method for raising an immune response in an appropriate mammal, comprising administering a pharmaceutical composition of the invention to the appropriate mammal. The immune response is preferably protective and it preferably involves antibodies. More particularly, the immune response is protective against GBS and preferably involves antibodies against GBS. The method can raise a response to a callback. The suitable mammal is preferably a human. When the vaccine is intended for use BE2017 / 5163 prophylactic, the human being is preferably a child (for example, a young child or an infant) or an adolescent; when the vaccine is intended for therapeutic use, the human being is preferably an adult. A vaccine for children can also be given to adults, for example, to estimate safety, dosage, immunogenicity, etc. A preferred class of humans for treatment are women of childbearing age (for example, adolescent girls and beyond). Another favorite class is pregnant women. Elderly patients (for example, those over the age of 50, 60, 70, 80 or 90, etc., especially over 65), especially those living in nursing homes where the risk of infection by GBS may be increased (reference 86), constitute another preferred class of human beings for treatment. Women with undetectable levels of antibodies to the GBS capsular saccharide (s) may experience higher rates of GBS infection in their newborns. This is due to the fact that higher levels of maternal antibodies to GBS capsular saccharides are correlated with a reduced risk of disease in newborns (references 87 and 88). Therefore, administration to these women is specifically contemplated in the present invention. The invention also provides a composition of the invention for use as a medicament. The drug is preferably capable of raising an immune response in an appropriate mammal (this is 29 BE2017 / 5163 i.e. it is an immunogenic composition) and it is more preferably a vaccine. The invention also provides the use of a composition of the invention in the manufacture of a medicament for enhancing an immune response in an appropriate mammal. These uses and methods can be intended for the prevention and / or treatment of a disease caused by S. agalactiae, for example, neonatal septicemia or bacteremia, neonatal pneumonia, neonatal meningitis, endometritis, osteomyelitis , septic arthritis, etc. These uses and methods may be intended for the prevention and / or treatment of a disease caused by S. pneumoniae, for example, bronchitis, rhinitis, acute sinusitis, otitis media, conjunctivitis, meningitis, bacteremia, sepsis, osteomyelitis, septic arthritis, endocarditis, peritonitis, pericarditis, cellulitis, and brain abscess. The subject in whom the disease is prevented may not be the same as the subject receiving the conjugate of the invention. For example, a conjugate can be administered to a woman (before or during pregnancy) to protect her offspring (the so-called "maternal immunization", references 89 to 91). One way of verifying the effectiveness of a therapeutic treatment involves monitoring the infection with GBS after the administration of the composition of the invention. One way to verify the effectiveness of prophylactic treatment involves monitoring immune responses against the target pathogen, for example, BE2017 / 5163 GBS antigens after administration of the composition. The preferred compositions of the invention can confer an antibody titer in a patient which is greater than the criterion for seroprotection for each antigenic component for an acceptable percentage of human subjects. Antigens with an associated antibody titer above which a host is considered to have undergone seroconversion against the antigen are well known, and such titles are published by organizations such as WHO. Preferably, more than 80% of a statistically significant sample of subjects has undergone seroconversion, more preferably more than 90%, even more preferably more than 93% and most preferably 96 to 100% The compositions of the invention will generally be administered directly to a patient. Direct administration can be accomplished by parenteral injection (e.g., subcutaneously, intraperitoneally, intravenously, intramuscularly, or into the interstitial space of tissue), or by rectal, oral, vaginal, topical, transdermal administration , intranasal, ocular, auricular, pulmonary or other mucosal. Intramuscular administration in the thigh or upper arm is preferred. The injection can be done using a needle (for example, a hypodermic needle), but needle-less injection can be used alternatively. A typical intramuscular dose is 0.5 ml. The invention can be used to trigger systemic and / or mucosal immunity. The treatment BE2017 / 5163 dosage can be a single dose schedule or a multiple dose schedule. Multiple doses can be used in a primary immunization schedule and / or in a booster immunization schedule. A primary dose schedule may be followed by a booster dose schedule. The appropriate time between sensitization doses (for example, between 4 and 16 weeks), and between sensitization and the booster, can be routinely determined. General The term "comprising" includes "including" as well as "consisting of", for example, a composition "comprising" X may consist exclusively of X or may include something additional, for example, X + Y. The term "substantially" does not exclude "completely", for example, a composition which is "substantially free" of Y can be completely free of Y. When necessary, the term " noticeably " can be left out of the definition of 1 1 'invention. In certain put in work, the term " including » relates to 1 ' inclusion of The agent indicated active ingredient, such as the polypeptides mentioned, as well as the inclusion of other active agents, and of supports, excipients, emollients, stabilizers, etc. pharmaceutically acceptable, which are known in the pharmaceutical industry. In certain implementations, the term “consisting essentially of” relates to a composition, the only active ingredient of which BE2017 / 5163 is the indicated active ingredient (s), however, other compounds which are intended for stabilization, preservation, etc. may be included. of the formulation, but which are not directly involved in the therapeutic effect of the active ingredient indicated. The use of the transition phrase "essentially constituted" means that the scope of a claim is to be interpreted as encompassing the specified materials or steps cited in the claim, and those which do not materially affect the basic characteristic (s) and news of the claimed invention. See, In re Herz, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976) (in italics in the original); see also MPEP § 2111.03. Thus, the term "consisting essentially of", when used in a claim of this invention, is not intended to be interpreted as being equivalent to "comprising". The term "consisting of" and its variations includes "including and limited to" unless expressly stated otherwise. In some jurisdictions, the term "comprising an active ingredient made up of" may be used in place of "made up essentially". The term "approximately" in relation to a numerical value x means, for example, x + 10%, x + 5%, x + 4%, x + 3%, x + 2%, x + 1%. The term "substantially" does not exclude "completely", for example, a composition which is "substantially free" of Y may be completely free of Y. Where necessary, the term "substantially" may be omitted from the definition of the invention. BE2017 / 5163 Unless otherwise specified, a process comprising a step of mixing two or more components does not require any specific order of mixing. Thus, the components can be mixed in any order. When there are three components, then two components can be combined with each other, and then the combination can be combined with the third component, etc. Antibodies will generally be specific to their target. Thus, they will have a higher affinity for the target compared to an irrelevant control protein, such as bovine serum albumin. Examples Example 1 Bacterial strains - The GBS strain of serotype III COH1 (serotype III) was obtained from Dennis Kasper (Harvard Medical School, Boston, MA). Isolation and purification of the capsular polysaccharide of serotype III - The SGB COH1 strain was used for the preparation of PSC III from 1 liter of bacterial culture developed until the exponential phase in Todd Hewitt broth. The purification process was based on previously described procedures (Wessels M. R., 1990 J. Clin. Investig. 86, 1428-1433). Briefly, the bacterial pellet was collected by centrifugation at 4000 rpm for 20 min and incubated with 0.8 N NaOH at 37 ° C for 36 h. After centrifugation at 4000 rpm for 20 min, 1 M Tris buffer (1/9, v / v) was added to the supernatant and BE2017 / 5163 diluted with HCl (1/1, v / v) to reach a neutral pH. To further purify the serotype III PSC, 2 M CaCl2 (final concentration 0.1 M) and ethanol (final concentration 30% (v / v)) were added to the solution. After centrifugation at 4000 xg for 20 min, the supernatant was subjected to tangential flow filtration with a molecular weight threshold of 10,000 (Hydrosart Sartorius; surface of 0.1 m 2 ) against 14 volumes of 50 mM Tris, 500 mM NaCl, pH 8.8 and 7 volumes of 10 mM sodium phosphate, pH 7.2. EXAMPLE 2 Fragments of the Polysaccharides of Serotype III Prepared by Deamination The native serotype III PS was partially N-deacylated as follows: the polysaccharide was dissolved in 3 ml of 0.5 M NaOH, heated at 70 ° C for 2 to 4 h, and then frozen in an ice-water bath . Glacial acetic acid was added to the sample to bring the pH to 4.5. The partially N-deacylated product was deaminated by the addition of 200 μΐ of 5% NaNO 2 (w / v) and stirred at 4 ° C for 2 h. The material was purified by a G25 column eluting with water. To reconstitute the full N-acetylation of sialic acid residues, a solution diluted to 1/1 of 4.15 μΐ / ml of acetic anhydride in ethanol was added, and the reaction was incubated at room temperature for 2 h. The material was purified by a G25 column eluting with water. BE2017 / 5163 Example 3 Purification of the Oligosaccharides Fragments of different length were separated by anion exchange chromatography using a semi-preparative HPLC with a MONO Q ™ column. By increasing the percentage of NaCl in the elution buffer with a stepped gradient, it was possible to isolate oligosaccharides with a difference in chain length (degree of polymerization or DP) in the range of 1 to 2 repeating units ( UR) (Figure 2) These fragments consisted of a modified UR and a variable number of unmodified URs. The length of the oligosaccharides was determined by 4 H NMR analysis (Figure 3). The ratio between the proton signal integral of the furanoside aldehyde proton generated during the depolymerization reaction (at 6.62 ppm in the form of hemi-acetal) and the proton signals associated with the other monosaccharides was used to measure the length of the oligosaccharide. The length of DP2 was confirmed by mass spectrometry (MALDI TOF) in negative mode using BE2017 / 5163 dihydroxybenzoic acid as matrix (MS found: 1938.21; calculated: 1937.70). The DP2 contains two repeating units: a repeating unit and an appendix consisting of a modified repeating unit. This nomenclature (for example, DP3, DP4) will be used below. To corroborate the integrity of the DP2 and DP3 obtained observed by the NMR analysis, an HPAEC-PAD analysis was carried out with a Dionex ICS3000 equipped with a CarboPac PA1 column. The PSIII was used as a control. The relative ratio of the various sugars making up the polymer was determined (Table 1), indicating that no significant loss of sialic acid was produced during the depolymerization. Considering that a GlcNAc residue was lost in the entire molecule (the one which was to become a 2,5-anhydro-Dmannose residue during the reaction), the length of the oligosaccharide was estimated using the formula: DP = [X] / ([X] - [GlcNAc]) where [X] represents the concentration of Glc or half the concentration of Gai. The PDs estimated (Table 4.1) by this method were in good agreement with the length estimated via NMR and MS analysis. Table 1 Quantification by HPAEC-PAD of the monosaccharide components and estimation of the relative length BE2017 / 5163 Sample GlcNAcpmol / ml Glcpmol / ml Cheerfulpmol / ml NeuNAcpmol / ml DPcalculatedbyGlcNAc DP2 7.71 13.79 30.75 12.91 2.1 DP3 9, 81 14.86 29.46 14.31 30 PSIII 5, 86 5, 97 12.06 5, 83 not. at. PSIII refers to the native polysaccharide of GBS serotype III. Example 4 - Synthetic structures (Figures 4A to D) General procedures for the chemical synthesis of oligosaccharides All of the chemicals were reactive grade, and were used without further purification. The reactions were followed by thin layer chromatography (TLC) on silica gel 60 F254 (Sigma Aldrich); after examination under UV light, the compounds were visualized by heating with ethanolic H2SO4 at 10 (v / v) In the preparation procedures, the organic solutions were washed with the amounts of the aqueous solutions indicated, then dried with anhydrous Na2SO4, and concentrated under reduced pressure at a temperature of 30 to 50 ° C on a water bath. Column chromatography was carried out on pre-filled cartridges of REDISEP ™ silica (Teledyne-Isco, 0.040 to 0.063 nm) or BIOTAGE ™ SNAP Ultra (0.050 nm of irregular silica). Unless otherwise specified, a gradient of 0 100% of the elution mixture was applied in a COMBIFLASH ™ instrument BE2017 / 5163 Rf (Teledyne-Isco) or ISOLERA ™ (Biotage). Mixtures of less polar solvents than those used for TLC were used at the start of the separation. The 3 H NMR spectra were measured at 400 MHz and 298 K with a Bruker AVANCE ™ III spectrometer; the values of δΗ were reported in ppm, compared to the internal standard Me4Si (δΗ = 0.00, CDCI3) or the water signal (δΗ = 4.79 ppm, D2O). The 13 C NMR spectra were measured at 100 MHz and 298 K with a Bruker Avance 111 spectrometer; ôc values are reported in ppm with respect to the CDCI3 signal (ô c = 77.0, CDCI3). NMR signals were assigned by homonuclear and heteronuclear correlation dimensional spectroscopy. When reporting the assignments of NMR signals, the sugar residues in the oligosaccharides are indicated with capital letters, the uncertain assignments are indicated by The nuclei associated with the linker are indicated with a premium. The exact masses were measured by electrospray ionization threshold spectroscopy, using a Q-Tof fflicroMacromass (Waters) instrument. Optical rotation was measured with a Jasco P2000 at 25 ° C. Figure 4A provides the structure of the repeating unit of the GBS polysaccharide of serotype III (GBS PSIII). Figures 4B to 4D provide the structures of the synthetic pentasaccharide fragments of the PSIII of GBS (Compounds 1, 2, and 3, respectively). BE2017 / 5163 Example 5 - Synthesis of fragment 1 (Figure 5) Diagram 1. Reagents and conditions: a. NaOMe, MeOH; (CH 3 ) 2 C (OCH 3 ) 2 , DMF, PTSA, 50 ° C, then TEA, 9/1 mixture of MeOH-H 2 O, 90 ° C; BnBr, 60% NaH, DMF, 57% (on steps); b. 4/1 mixture of AcOH-H 2 O, 70 ° C; (EtO) 3 CCH 3 , PTSA, CH 3 CN, then 4/1 mixture of AcOH-H 2 O, 65% (on stages); vs. NIS, TfOH, DCM, -20 ° C, 72%; d. 4/1 mixture of AcOH-H 2 O, 70 ° C; TBDPSC1, DMAP, Py, 60 ° C, 80% (over 2 steps); e. Cs 2 CO 3 , CF 3 CClNPh, DCM, 82%; f. TMSOTf, DCM, 55%; g. Lil, Py, 120 ° C; H 2 NCH 2 CH 2 NH 2 , EtOH, 90 ° C; Ac 2 O-Py; NaOMe, MeOH; H 2 , Pd-C, 31%. he· 2,4,6-tri-0-benzoyl-3-0 (4,7,8,9-tetra-O-acetyl-5- (N-acetamido) 3,5-dideoxy-Dglycero-aD-galacto trifluoroacetimidate -methyl non-2-ulopyranosylonate) -D-galactopyranosyl-N-phenyl (α, β) 11 To a solution of compound 10 (1.5 g, 1.4 mmol) in DCM (10 ml) and 2,2,2-trifluoro-Nphenylacetimidoyl chloride (3 equivalents), Cs 2 CO 3 (1 equivalent ) was added at 0 ° C, and the reaction was stirred at RT for 3 h. The solid was separated by filtration and the solvent was evaporated. The crude product was purified by flash chromatography (8/2 mixture of toluene / acetone) to produce compound 11 in the form of a brown foam in a yield of 82% (1.15 g). HR ESI-MS m / z C 5 5H 5 5F 3 N 2 O 21 [M + Na] + 1159, 3147; found 1159.3065. (Ando et al. Carbohydrate Research 338 (2003) 503-514). BE2017 / 5163 2,6-Di-O-benzyl-3,4-di-0-isopropylidene-3-Dgalactopyranosyl- (1 ^ 4) -2,3,6-tri-0-benzyl-3-D-glucopyranoside de 3- azidopropyl 5 The known compound 4 (5.0 g, 11.7 mmol) was dissolved in 100 ml of 9/1 mixture of 2,2-dimethoxy-propane / DMF. Catalytic PTSA (0.2 equivalent) was added and the reaction was warmed to 50 ° C for 3 h. TLC (9/1 mixture of DCM / MeOH) showed the disappearance of the starting material and the formation of 2 spots, accompanied by other by-products. The reaction was quenched with TEA to neutral pH, and the solvent was removed under reduced pressure. The crude product was dissolved in 150 ml of 9/1 mixture of MeOH / H 2 O and reheated at 90 ° C for 2 h, when the presence of a major spot was detected by TLC. The solvent was removed under reduced pressure, and the crude product was purified by flash chromatography (9/1 mixture of DCM / MeOH) to give isopropylated galactose in a yield of 72% (3.9 g). The upcoming compound was dissolved in dry DMF (50 ml) under a nitrogen atmosphere. The solution was cooled to 0 ° C, and 60% NaH (2.2 g, 55.25 mmol) was added in parts. After 20 min, BnBr (10.3 ml, 85 mmol) and TBAI (7.8 g, 21.25 mmol) were added. BE2017 / 5163 The reaction was stirred overnight at RT, then neutralized by the addition of MeOH and the solvent was removed under reduced pressure. The crude product was dissolved in CH2Cl2, washed twice with aqueous NaHCO 3 and once with water. The organic phase was collected, dried with Na 2 SO4 and evaporated under reduced pressure. The crude product was purified by flash chromatography (8/2 mixture of cyclohexane / EtOAc) to give compound 5 in a yield of 79% in the form of a pale yellow oil (6.1 g). HR EST-MS m / z N 3 0h [M + Na] + 938.4204 ; found 938.4200 • 3 H NMR (400 MHz, CDC1 3 ): δ 7.50-7.20 (m, 25H, H- 4.99 - 4.35 (m, 12H, CiLPh, including, 4.45, d, H- 1a, J = 8.0 Hz, 1H; 4.39, d, H-lb, J = 8.7 Hz, 1H), 4.15 (dd, 1H, J = 5.5, 1.1 Hz, H-4a), 4.07-3.96 (m, 3H, OCH 2a , H-3, H-4), 3.86 (dd, 1H, J = 10.9, 4.1 Hz, H- 6b ), 3, from 80 to 3.70 (m, 3H, H-6b, H-6, H-3), 3.67 (m, 1H, OCH 2 b), 3, 64 to 3.54 (m, 2H , H-6, H-5), 3.48 to 3.35 (m, 5H, H-2a, H2b, CH 2 N 3, H-5), 1.93 (m, CH 2 CH 2 N 3, 2H), 1.45 (s, 3H, C (CH 3 )), 1.40 (s, 3H, C (CH 3 )). NMR 13 C (101 MHz, CDC1 3 ) δ 138, 95-12 6, 96 (50 x C-Ar, C (CH 3 ) 2 ), 109, 78, 103.58 (Clb), 101.85 (Cia ), 82, 98, 81.80 (C2b), 80, 63 (C2a), 79, 37, 77.25, 76, 29, 75.43, 75.07-73.20 (5xCH 2 Ph), 72 , 01, 68.94 66, 48 (OCH 2 ), 65.30, 48.33 (CH 2 N 3 ), 27, 98, 26, 42 (2 x C (CH 3 )). (C6a), 68.18 (C6b), 29, 27 (CH 2 CH 2 N 3 ), BE2017 / 5163 4-O-Acetyl-2,6-di-O-benzyl-ß-D-galactopyranosyl (1 ^ 4) -2,3,6-tri-O-benzyl-ß-D-glucopyranoside of 3azidopropyl 6 Lactoside 5 (6.1 g, 6.7 mmol) was suspended in a 4/1 mixture of AcOH / H 2 O (200 ml). The reaction was warmed to 70 ° C for 2 h. TLC (7/3 mixture of cyclohexane / ethyl acetate) showed the disappearance of the starting material and the formation of a spot with a lower Rf. The solvent was removed under reduced pressure and the crude product was coevaporated with toluene (3 x 100 ml). The crude product was dissolved in CH 3 CN (100 ml), then triethyl orthoacetate (3.7 ml, 20.1 mmol) and PTSA (270 mg, 1.34 mmol) were added. The reaction was stirred at RT for 4 h, then the solvent was removed under reduced pressure. The crude product was dissolved in a 4/1 mixture of AcOH / H 2 O (100 ml) and after 2 h, the solvent was removed under reduced pressure. The crude product was purified by flash chromatography (6/4 mixture of cyclohexane / EtOAc) to give compound 6 in an overall yield of 65% (3.9 g) in the form of a pale yellow oil. HR ESI-MS m / z C5 2 H 5 9N 3 Oi 2 [M + Na] + 939.3996; found 940.4030. NMR Χ Η (400 MHz, CDC1 3 ) δ 7.47-7.13 (m, 25H, H-Ar), 5.37 (d, J = 3.2 Hz, 1H, H-4 B ), 5.01-4.63 (m, 7H, 7 x CHHPh), 4.53-4.43 (m, 3H, including, 2 x CHHPh, H-la; 4.39, d, J = 7.8 Hz, 1H, H-1 B ), 4.27 (d, J = 12.0 Hz, 1H, CHHPh), 4.01 (m, 2H, 1 x OCH 2a , H-4 A ), 3.82 (dd, J = 10.9, 3.9 Hz, 1H, H-6 A ), 3.75 (d, J = 9.7 Hz, 1H, H-6a), 3,693.49 (m, 5H, H-3 B , OCH2b, H- 6 b , H-4 B , H-5 B ), 3.48 - 3.31 BE2017 / 5163 (m, 7H, CH 2 N 3 , H-2 A , H-2 b , H-3 CH 3 CO), 1.92 (m, 2H, CH 2 N 3 ). 13 C NMR (101 MHz, CDC1 3 ) 126 .97 (Because) , 103, 57 (C-l 80, 08 (C-2 A , C-2 A ), 76, 28, 72, 43, 71, 98 (C-3 A , C-3A) 67, 23 (OCH 2 ), 66, 50 (C-6 A ), 20, 78 (CH 3 CO) -, H-5 A , H-6 A ), 2.06 (s, 3H, δ 171.00 (COCH 3 ), 138, 99 102.30 (C-1 B ), 82.71, 81, 68, j, 25, 75, 04, 73.39, 73.23, 9.63 (C-4 B ), 68, 09 (C-6 B ),, 30 (CH 2 N 3 ), 29, 25 (CH 2 CH 2 N 3 ), ...... GBn at 3-O-Benzyl-4,6-0-benzylidene-2-deoxy-2phthalimido-glucopyranosyl- (1 ^ 3) -4-O-acetyl-2, 6-di-Obenzyl-ß-D-galactopyranosyl- (1 ^ 4) -2,3,6-tri-O-benzyl-ßD-3-azidopropyl glucopyranoside 8 A solution of acceptor 6 (800 mg, 0.87 mmol) and known donor 7 (655 mg, 1.13 mmol) with activated molecular sieves (4 Â, 1.0 g) in DCM (10 ml ) was stirred for 20 min under nitrogen. NIS (508 mg, 2.26 mmol) and TfOH (20 μΐ, 0.23 mmol) were added at -20 ° C. After stirring the reaction mixture for 24 h at room temperature, TEA was added until neutral pH, the solid was separated by filtration and the solvent was removed at reduced pressure. The crude product was purified by flash chromatography (4/1 toluene / EtOAc mixture) to give compound 8 in a yield of 72% (870 mg) in the form of a BE2017 / 5163 colorless oil. HR ESI-MS m / z C80H82N4O18 [M + Na] + 1409.5522; found 1409.5604. 4 H NMR (400 MHz, CDC1 3 ) δ 7.47-7.13 (m, 39H, H-Ar), 5.55 (s, 1H, CHPh), 5.31-5.27 (m, 2H, Hl c , H-4 B ), 4.834.52 (m, 5H, CHHPh), 4.45-4.33 (m, 5H, 4 x CHHPh, H-4 C ), 4.21-3.39 (m, 6H, H-1 A , Hl b , H-2 C , 3 x CHHPh), 3.85-3 , 71 (m, 5H, H-2 A_B , H-6 a A_c ), 3.62-3.18 (m, 15H, H3 A ' C , Η-4 Α - °, x H-5, H- 6 b A_c , OCH 2 , CH 2 N 3 ), 2, 97-2, 90 (m, 1H, H-5), 2.02 (s, 3H, CH 3 CO), 1.82-1.69 (m, 2H, CH 2 CH 2 N 3 ). 13 C NMR (101 MHz, CDC1 3 ) 139.04-123.14 (C-Ar), 103.46 101.27 (CHPh), 99, 20 (C-lc c ), 82.83 (C-2 A ), 82, 65, 78, 88, 78, 63, 75, 66, 75, 16, 75, 04 , 74, 68, 74.43 (C-2 B ), 74.31 (CH 2 Ph), 74.26 (CH 2 Ph), 74, 04 (CH 2 Ph), 73.55 (CH 2 Ph) , 73.11 (CH 2 Ph), 72, 82 (CH 2 Ph), 72.49 (C-3 C ), 69, 85 (C-4 C ), 68.76, 68.50, 68.21, 67, 61, 66, 25, 65, 91 (C-6 A ), 65.91 (C-6 B ), 66, 39 (OCH2), 65.91 (C-6 C ), 56.11 (C -2 C ), 48.29 (CH2N 3 ), 29.21 (CH 2 CH 2 N 3 ), 20.88 (CH 3 CO). δ 169, 90, 167.50 (CO), (C-1 A ), 101.87 (C-1 B ), 3-O-Benzyl-6-0-t-butyldiphenylsilyl-2-deoxy-2phthalimido-glucopyranosyl- (1AS) -4-O-acetyl-2,6-di-Obenzyl-ß-D-galactopyranosyl- (U4) - 2,3,6-tri-O-benzyl-ßD-glucopyranoside of 3-azidopropyl 9 Trisaccharide 7 (0.29 mmol, 400 mg) was suspended in a 4/1 mixture of AcOH / H 2 O (25 ml). The BE2017 / 5163 reaction was warmed to 70 ° C and stirred for 4 h. The solvent was removed at reduced pressure and the crude product was purified by flash chromatography (mixture 6/4 of cyclohexane / EtOAc) to produce the debenzylidine trisaccharide in a yield of 87% (325 mg, 0.25 mmol) in the form of a pale yellow oil. The material was dissolved in pyridine (10 ml). TBDPSC1 (0.50 mmol, 140 μΐ) and DMAP (0.05 mmol, 10 mg) were added and the reaction was stirred overnight at 60 ° C, when the TLC (7/3 mixture of cyclohexane / EtOAc) showed a complete reaction. The solvent was removed at reduced pressure and the crude product was purified by flash chromatography (cyclohexane / EtOAc) to give compound 9 in 92% yield (675 mg) as a yellow oil. HR ESI-MS m / z CggHÄOigSi [M + Na] + 1159, 6387; found 1559.6224. 3 H NMR (400 MHz, CDC1 3 ) δ 7.31-7.14 (m, 44H, H-Ar), 5.38-5.32 (m, 2H, H-lc, H-4b), 4.91 (d, J = 10.5 Hz, 1H, CHHPh), 4.86-4.36 (m, 7H , CHHPh), 4.33 (dd, J = 11.4, 2.8 Hz, 1H, H-4 C ), 4.30-4.18 (m, 6H, H-1 A , H-lb, 4 x CHHPh), 4.17-4.08 (m, 2H , H-2 C , H-6a), 4.02 (m, 2H, H-6 C , H-3), 3.95-3.83 (m, 3H, H-4 A , OCH2a), 3 , 63 (m, 1H, H-5), 3.60-3.45 (m, 3H, H-5 B , H-6 a , OCH 2b ), 3.45-3.23 (m, 9H, CH 2 N 3 , H-6 a , 2 x H-6 b , H-2 A , H-2 B , 2 x H-3), 3.04 (d, J = 9.5 Hz, 1H, H-5), 2.02 (s, 3H, CH 3 CO), 1.92-1.82 (m, 2H, CH 2 CH 2 N 3 ), 1.12 (s , 9H, t-Bu). 13 C NMR (101 MHz, CDC1 3 ) δ 169, 80, 166, 70 (CO), 135.59-120.48 (C-Ar), 103.41 (C-1 A ), 101.82 (C-1 B ), 98.41 (Cl c ), 82.58, 81.53, 79 , 11, 78.44, 77.72, 75, 48, 75, 09, 75.00, 74.96, 74.69, 74.33, 74.20, 73.90, 73.38, 73.07, BE2017 / 5163 72.71, 69, 93 (C-4 C ), 68.34 (C-6b), 67, 62 (C-6a), 66.35 (OCH2), 65.31 (C-6 C ), 55 , 75 (C-2 C ), 48.25 (CH2N 3 ), 31.07 (C (CH 3 ) 3 ), 29.18 (CH 2 CH 2 N 3 ), 26, 83 (C (CH 3 ) 3 ), 20, 66 (CH 3 CO). 0- [4,7,8,9-Tetra-O-acetyl-5- (N-acetamido) -3,5dideoxy-D-glycero-aD-galacto-non-2-ulopyranosylonate] - (2 ^ 3 ) -Ο- (2,4,6-tri-O-benzoyl-ß-D-galactopyranosyl) - (1 ^ 4) -3,6-0-benzyl-2-d0soxy-2-phthalimido-ßD-glucopyranoside) - (1 ^ 3) -4-O-acetyl-2,6-O-benzyl-ß-Dgalactopyranosyl- (1 ^ 4) -2,3,6-tri-O-benzyl-ß-D-glucopyranoside de 3 -azidopropyl 12 A solution of acceptor trisaccharide 9 (675 mg, 0.23 mmol) and donor disaccharide 11 (261 mg, 0.23 mmol) with activated 4 Å molecular sieves (800 mg) in DCM (8 ml) was stirred for 20 min under nitrogen. TMSOTf (0.046 mmol, 9 μΐ) was added at 0 ° C. Then the reaction mixture was stirred for 10 h at RT, when the TLC (7/3 mixture of toluene / acetone) showed a complete reaction. TEA was added until neutral pH, the solid was separated by filtration and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography (toluene / acetone) to give compound 12 in a yield of 55% (314 mg) in the form of an amorphous solid. HR ESI-MS m / z CisgH ^ sNsOsgSi [M + Na] + 2506, 9235; found 2506.9224. BE2017 / 5163 3 H NMR (400 MHz, CDC1 3 ) δ 8.28-7.11 (m, 59H, H-Ar), 5.73 (ddd, J = 2.2, 6.0, 9.2 Hz, IH, H-8 E ), 5.54 (dd, J = 8.0, 10.2 Hz, IH, H-2 D ), 5.37 (m, J = 3.5 Hz, IH, H7 E ), 5.28-5.22 (m, 3H, H-1 D , H-4 B , H-4 D ), 5.17 (d, J = 8.4 Hz, IH, Hl c ), 4.96-4.61 (m, 9 H, including m, 4.81, H-4 E and m, 4.62, H-6 E ), 4 , 48-4, 00 (m, 15H), 3.89-3.79 (m, 7H, including m, 5.02, H-5 E , and s, 3.83, COOCH 3 ), 3.653, 62 (m, 1H), 3.59-3.50 (m, 1H, OCH 2b ), 3.45-3.24 (m, 10H), 2.97-2.95 (m, IH), 2.46 (dd, J = 4.5, 12.6 Hz, 1H, H-3 e E ), 2.18, 2, 15, 2, 11, 2.03, 1.96 (5 x s, 3H each, 5 CH 3 CO), 1, 89-1 , 80 (m, 5 H, CH 2 CH 2 N 3 , including s, 1.83, CH 3 CO), 1.70 (t, J = 12.0 Hz, H-3 to E ), 1.60 (s, 9H, t-Bu). 13 C NMR (101 MHz, CDC1 3 ) δ 17 0.70-164, 81 (C = O), 138, 91-125.28 (C-Ar), 103.39 (C-1 A / E ), 102.00 (C-1 A / E ), 99, 88 (C-1 D ), 97.45 (Cl c ), 82.48, 81.61, 80.05, 78.43, 78.31, 77.32, 77.21 , 77.01, 76, 69, 75.52, 75.43, 75.08, 75.00, 74.85, 74.72 , 74.30, 74.14, 73.31, 73.00, 72.61, 72.27, 72.21, 71.71 , 70.80, 69.78, 69, 30, 68.58, 68.14, 67.83, 67.69, 66, 54 , 66.35, 62.51, 62.11, 56, 54 (C-2 C ), 53, 04 (C-5 E ), 49, 02 (COOCH 3 ), 48.27 (CH 2 N 3 ), 37.39 (C-3 E ), 29.26 (C (CH 3 ) 3 ), 29, 21 (CH 2 CH 2 N 3 ), 26, 80 (C (CH 3 ) 3 ), 23, 16, 21.44, 21.21, 20.75 , 20.71, 19.36 (6 x CH 3 CO). Example 6 - Synthesis of fragment 2 (Figure 6) Figure 2. Reagents and conditions: a. HO (CH 2 ) 3 N 3 , NIS, TfOH, 84%; b. 4/1 mixture of AcOH-H 2 O, 70 ° C; TBDPSC1, DMAP, Py, 60 ° C, 70% (over 2 steps); vs. TMSOTf, DCM, 70%; d. HF-Py, 4/1 mixture of THF-Py, ° C at RT, 78%; e. AgOTf, DCM, 68%; f. Lil, Py, 120 ° C; H 2 NCH 2 CH 2 NH 2 , EtOH, 90 ° C; Ac 2 O-Py; NaOMe, MeOH; H 2 , Pd-C, 42%. BE2017 / 5163 4,6-0-Benzylidene-3-0-benzyl-2-deoxy-2phthalimido-ß-D-glucopyranoside from 3-azidopropyl 13 A solution of Compound 7 (2.0 g, 3.45 mmol) and 3-azido-1-propanol (707 mg, 7.0 mmol) with activated molecular sieves (4 Â, 3.0 g) in DCM (25 ml) was stirred for 20 min under nitrogen. NIS (1.57 g, 7.0 mmol) and TfOH (61 μΐ, 0.7 mmol) were added at -10 ° C. After 12 h (TLC; 7/3 mixture of cyclohexane / EtOAc), the reaction was neutralized with TEA, the solid was separated by filtration and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography (cyclohexane / EtOAc) to give compound 13 in a yield of 84% (1.65 g) in the form of a yellow oil. The NMR data were consistent with those reported in the literature (J Carbohydr Chem 24: 755-769, 2005). Îianir E! 3-O-Benzyl-6-0-t-butyldiphenylsilyl-2-deoxy-2phthalimido-ß-D-glucopyranoside from 3-azidopropyl 14 Monosaccharide 13 (1.65 g, 2.9 mmol) was suspended in a 4/1 mixture of AcOH / EhO (40 ml). The BE2017 / 5163 reaction was warmed to 70 ° C and allowed to stir for 4 h. The solvent was removed under reduced pressure and the crude product was purified by flash chromatography (6/4 mixture of cyclohexane / EtOAc) to produce 3-0-benzyl-2-däsoxy-2-phthalimido-ß-Dglucopyranoside of 3 -azidopropyl in a yield of 89% (1.24 g, 2.6 mmol) in the form of a pale yellow oil. The material was dissolved in pyridine (20 ml). TBDPSC1 (1.34 ml, 5.2 mmol) and DMAP (65 mg, 0.52 mmol) were added and the solution was stirred overnight at 60 ° C, when the reaction was complete (TLC, 8/2 mixture of cyclohexane / EtOAc). The mixture was diluted with DCM and washed with water. The organic phase was dried with Na2SO4 and evaporated under reduced pressure. The crude product was purified by flash chromatography (cyclohexane / EtOAc) to give compound 17 in a yield of 79% (1.48 g) in the form of a pale yellow oil. HR ESI-MS m / z C4oH44N 07Si 4 [M + Na] + 743.2877; found 743.2819. NMR 3 H (400 MHz, CDC1 3 ) δ 8, 12-6, 84 (m, 19H, H-Ar), 5, 17 (d, J = 8.4 Hz, 1H, H-1), 4.82, 4.59 (2 d, J = 12.2 Hz r 1H, CH 2 Ph), 4.30 (dd, J = 10.7, 8.5 Hz , 1H, H-3), 4, 17 (dd , J = 10 , 7, 8 , 5 Hz, 1H, H-2), 4.06-3 , 96 (m, 2H, 2 x H-6) , 3.92 (t, J = 9.0 Hz, 1H, H-4), 3, 76-3.82 (m, 1H, OCH 2 a), 3.63 (dt, J = 9.8, 5.1 Hz, 1H, H-5), 3.543.40 (m, 1H, OCH 2 b), 3.12 (m, 2H, CH 2 CH 2 N 3 ), 1.78-1.57 (m, 2H, CH 2 N 3 ), 1.13 (s, 9H, t-Bu). 13 C NMR (101 MHz, CDC1 3 ) δ 167.81 (CO), 138.22127.41 (C-Ar), 98.14 (Cl), 78.79 (C-3), 74.60, 74 , 38, 74.33 (CH 2 Ph, C-4, C-5), 65, 82 (OCH 2 ), 65, 09 (C-6), 55.35 (C-2), 48, 00 (CH 2 N 3 ), 31.04 (C (CH 3 ) 3 ), 28.81 (CH 2 CH 2 N 3 ), 26, 82 (C (CH 3 ) 3 ). BE2017 / 5163 0- [4,7,8,9-Tetra-O-acetyl-5- (N-acetamido) -3,5 dideoxy-D-glycero-aD-galacto-non-2-ulopyranosylonate] - (2 ^ 3 ) -Ο- (2,4,6-tri-O-benzoyl-ß-D-galactopyranosyl) - (1 ^ 4) -3-O-benzyl-6-Ot-butyldiphenylsilyl-2d0soxy-2-phthalimido-ß- 3-Azidopropyl D-glucopyranoside 16 A solution of donor disaccharide 11 (500 mg, 0.44 mmol) and acceptor 14 (320 mg, 0.44 mmol) with activated molecular sieves (4 Å, 800 mg) in DCM (8 ml) was stirred for 20 min under nitrogen. TMSOTf (16 μΐ, 0.088 mmol) was added at -10 ° C. After stirring for 10 h at RT, the TLC showed a complete reaction (7/3 mixture of toluene / acetone). TEA was added until neutral pH, the solid was separated by filtration and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography (toluene / acetone) to give compound 16 in a yield of 70% (520 mg) in the form of a glassy solid. HR ESI-MS m / z C 8 7H 93 N 5 O 2 7 Si [M + Na] + 1690.5275; found 1690.5801. RMN B H (400 MHz, CDC1 3 ) δ 8.32-6.52 (m, 34H), 5.57 (dd, J = 7.2, 9.0 Hz, 1H, H-2 B ), 5 , 45 (d, J = 3.3 Hz, 1H, H-4 B ), 5.35 (d, J = 7.8 Hz, 1H, H-1 A ), 5.27 (dd, J = 9.2, BE2017 / 5163 2.4 Hz, 1H, H-8 C ), 5.02 (d, J = 10.0 Hz, H-1 B ), 5.04-4.93 (m, 1H), 4.80-4 , 77 (m, 2H), 4.71 (d, J = 12.4 Hz, 1H, CHHPh), 4.43-4.17 (m, 8H), 4.10 (dd, J = 10.6, 8.6 Hz, 1H), 4.02 (dd, J = 12.6, 4, 6 Hz, 1H), 3.92-3.77 (m, 3H), 3.73 (s, 3H, COOCH 3 ), 3.66 (dd, J = 10.8, 2.5 Hz, 1H), 3.58-3.53 (m, 1H, OCH 2b ), 3.31 (d, J = 9.6 Hz, 1H, H-6 b A ), 3.23-3.17 (m, 1H, H-5 B ), 3.01 (t, J = 6.8 Hz, 2H, CH 2 N 3 ), 2.41 (dd, J = 12.7, 4.6 Hz, 1H, H-3 e c ), 2.12, 1.98, 1.91, 1.81 (5 xs, 3H each, 5 x CH 3 CO), 1.70-1.67 (m, 2H, CH 2 CH 2 N 3 ), 1.62-1.60 (m, 4H, CH 3 CO, H-3 a c ), 1.07 (s, 9H, t-Bu). O- [4,7,8,9-Tetra-O-acetyl-5- (N-acetamido) -3,5dideoxy-D-glycero-aD-galacto-non-2-ulopyranosylonate] - (2 ^ 3 ) -O- (2,4,6-tri-O-benzoyl-ß-D-galactopyranosyl) - (1 ^ 4) -3-0-benzyl-2-deoxy-2-phthalimido-p-Dglucopyranoside 3- azidopropyl 17 Trisaccharide 16 (520 mg, 0.31 mmol) was suspended in a 4/1 mixture of THF / pyridine (10 ml) HF-py (930 μΐ) was added at 0 ° C. The solution was stirred overnight (TLC, 7/3 mixture of toluene / acetone), then the reaction was diluted with DCM and washed with water. The organic phase was dried with Na 2 SC> 4 and evaporated under reduced pressure. The crude product was purified by flash chromatography (toluene / acetone) to give compound 17 (345 mg) in a yield of 78% in the form of a solid BE2017 / 5163 glassy. HR ESI-MS m / z C7iH 75 N 5 O27 [M + Na] + 1452.4547; found 1452.4557. 3 H NMR (400 MHz, CDC1 3 ) δ 8.51-6.53 (m, 24H, H-Ar), 5.83 (td, J = 9.3, 2.4 Hz, 1H, H-8 C ), 5.55 (dd, J = 8.3, 10.5 H z, 1H, H-2 B ) , 5.32 (d, J = 3.2 Hz, 1H, H-4 B ), 5.20 (d, J = 10.2 Hz, 1H, H-1 A ), 5.13 (m, 2H, H-7 C , NH), 5.02 (d, J = 8.5 Hz, 1H, H-1 B ), 4.91 (d, J = 12.5 Hz, 1H, CHHPh) r 4.87 (dd, J = 3.0, 10.5 Hz, 1H, H -3 B ), 4.80 (dd, J = 4, 5, 10, 7 Hz, 1H, H-4 C ,), 4.61 (d, J = 12.5 Hz, 1H, CHHPh) r 4.55 (dd, J = 11.9, 2.4 Hz, 1H, H-6 C ), 4.49 (t, J = 9, 0 Hz, 1H, H -6 to B ), 4.30-4.09 (m, 5H, H-2 B , H-3 A , H- 5 B , H-6b B , H-6a A ), 3.95 (dd, J = 3.2, 9.0 Hz, 1H, H-9a c ), 3.89-3.75 (m, 7H , H-2 A , H-4 A , H-9b c , OCH2a, including s, 3.82, COOCH 3 ), 3.63 (dd, J = 10.7, 2.7 Hz, 1H, H-5 A ), 3.39-3.29 (m, 2H, OCH 2b , H-6 b A ), 3.16-2.99 (m, 2H, CH 2 N 3 ), 2.47 (dt, J = 13.6, 6.8 Hz, 1H, H-3 e c ), 2.18, 2.12, 1.75 (4 xs, 3H each, 4 x CH 3 ), 1.70-1.57 (m, 3H, H-3 a E , CH 2 CH 2 N 3 ). 13 C NMR (101 MHz, CDC1 3 ) δ 172.22, 171.43, 170, 98, 170.78, 170.60, 170.37, 170.25, 170.12, 169.17, 168.02, 167.58, 165.94, 165.83, 165 , 68, 165.49, 165.20 (C = O), 138.59-123.18 (Because), 100 .97 (C-1 B ), 98.19 (C-1 A ), 96, 82 (C-2 C ), 78.04 (C-3 A ), 76, 47 (C-4 A ), 75.20 (C-5 A ), 74, 44 (CH 2 Ph), 71.73 (C-3 B ) , 71 r 59 (C-2 B ), 71.46 (C-5 B ), 70, 62 (C-6 C ), 69.39 (C-4 B ), 68, 30 (C-8 C ), 67.36 (C-4 33 ), 66, 78 (C-7 C ), 65, 87 (OCH 2 ), 63.77 (C-9 C ), 61.71 (C-6 A / B ), 60.16 (C-6 A / B ), 55 , 67 (C-2 A ), 53.17 (C-5 C ), 48.53 (COOCH 3 ), 47.91 (CH 2 N 3 ), 37.31 (C-3 C ), 28.72 (CH 2 CH 2 N 3 ), 23, 02, 21.41, 21.35, 20.81, 20, 68, 20.45 (CH 3 CO). BE2017 / 5163 Ο- [4,7,8,9-Tetra-O-acetyl-5- (N-acetamido) -3,5dideoxy-D-glycero-aD-galacto-non-2-ulopyranosylonate] - (2 ^ 3 ) -O- (2,4,6-tri-O-benzoyl-ß-D-galactopyranosyl) - (1 ^ 4) - [(2,3,4,6-tetra-0-acetyl-pD-galactopyranosyl) - (1 ^ 4) - (2,3,6-tri-0-ac0tyl-ß-D-glucopyranosyl) - (1 ^ 6)] - 3-0-benzyl-2-d0soxy-2-phthalimido-ß- 3-azidopropyl 18 dglucopyranoside A solution of acceptor trisaccharide 18 (345 mg, 0.24 mmol) and donor 17 (420 mg, 0.60 mmol) with activated molecular sieves (4 Â, 800 mg) in DCM (8 ml) was stirred for 20 min under nitrogen. AgOTf (77 mg, 0.30 mmol) was added at 0 ° C. Then the reaction mixture was stirred for 10 h at RT, when the TLC (7/3 mixture of toluene / acetone) showed a complete reaction. TEA was added, the solid was filtered off and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography (toluene / acetone) to give compound 18 (300 mg, 0.14 mmol) in a yield of 68% in the form of a glassy solid. HR ESI-MS m / z C97HX09N5O44 [M + Na] + 2070, 6343; found 2070, 6296. NMR 3 Η (400 MHz, CDC1 3 ) δ 8.26-6, 73 (m, 24H, H-Ar), 5.73 (ddd, J = 2.2, 6.0, 9.2 Hz, 1H, H-8 E ), 5.53 (dd, J = 8.3, 10.5 Hz, 1H, H-2 B ), 5.36-5.31 (m, 2H), 5.2554 BE2017 / 5163 4.79 (m, 11H), 4-59-4.40 (m, 5H), 4.30-3.62 (m, 20H, including s, 3.82, COOCH 3 ), 3.41 -3.38 (m, 1H), 3.15-3.07 (m, 2H, CH 2 N 3 ), 2.47 (dt, J = 12.8, 4.6 Hz, 1H, H-3 e c ), 2.28, 2.19, 2.18, 2.17, 2.16, 2.11, 2.06, 2.05, 2.03, 1, 98, 1, 91, 1.75 (12 xs , 3H each, 12 x CH 3 ), 1, ΙΟΙ, 59 (m, 3H, H-3 a E , CH 2 CH 2 N 3 ). 13 C NMR (101 MHz, CDC1 3 ) δ 170, 91, 170.76, 170.52, 170.38, 170.22, 170.16, 170.10, 169.34, 168.15, 165.50, 164, 99 (C = O), 133.76-123.28 (C-Ar), 101.34 (C-1 D / E ), . 03 (C-1 D / E ), 100.72 (C-1 B ), 97.69 (C-1 A ), 96, 91, 79, 63 18, 75.05, 74.69, 72.96, 72.37, 71.74, 71.59, 71, 44, 35, 71.16, 71.05, 70.97, 70, 86, 70, 69, 70, 57, 69, 40, 00, 68.19, 6 6, 69, . 66.58, 66, 17 (4 x C-6), 55, 68 (VS- 2 A ), 53.19 (C-5 C ), 48.70 (COOCH 3 ), 47.96 (C-3 C ), 28, 67 (CH 2 CH 2 N 3 ), 23, 11, 22, 68, 20.80, 20.75, 20.73, 20.65, 20.54, 20.52 (CH 2 N 3 ), 37.25 21.44, 20, 86, (12 x CH 3 CO). Example 7 - Synthesis of fragment 3 (compound 3) (Figure 7) Scheme 3. Reagents and conditions: a. NaOMe, MeOH; 9/1 mixture of (CH 3 ) 2 C (OCH 3 ) 2 -DMF, PTSA, 50 ° C, then TEA, 9/1 mixture of MeOH-H 2 O, 90 ° C; BnBr, 60% Na H, DMF, 59% (over 3 steps); b. 4/1 mixture of AcOH-H 2 O, 70 ° C; (EtO) 3 CCH 3 , PTSA, CH 3 CN, then 4/1 mixture of AcOH-H 2 O, 80% (over 3 steps); vs. NIS, TfOH, DCM, -20 ° C, 72%; d. BH 3 -Me 3 , BF 3 -And 2 O, CH 3 CN, 64%; e. TMSOTf, DCM, 72%; f. DDQ, 4/1 mixture of DCM-MeOH, 85%; e. 65%; g. LU, Py, 120 ° C; H 2 NCH 2 CH 2 NH 2 , EtOH, 90 ° C; Ac 2 O-Py; NaOMe, MeOH; H 2 , Pd-C, 55%; h. NaOMe, MeOH; naphthylidene dimethyl acetal, DMF, PTSA, 50 ° C; BnBr, NaH at 60%, DMF, 63% (over 3 steps). BE2017 / 5163 2,6-O-Benzyl-3,4-0-isopropylidöne-ß-D-galactopyranoside of 3-azidopropyl 20 Compound 19 (3.0 g, 6.77 mmol) was dissolved in dry DMF (40 ml) under an atmosphere of nitrogen. The solution was cooled to 0 ° C, and a dispersion in 60% NaH mineral oil (704 mg, 17.6 mmol) was added in parts. After 20 min, BnBr (3.2 ml, 27.08 mmol) and TBAI (2.5 g, 6.7 mmol) were added. The reaction was stirred overnight at AT (TLC, 8/2 mixture of cyclohexane-EtOAc), then neutralized by the addition of MeOH and TEA. After removal of the solvent under reduced pressure, the crude product was dissolved in DCM and washed twice with aqueous NaHCO 3 and twice with water. The organic phases were combined, dried with Na 3 SO4, filtered and evaporated under reduced pressure. The crude product was purified by flash chromatography to give the compound 20 in a yield of 8 5 % (2, 75 g). HR ESI -MS m / z C26H 33 N 3 C> 6 [M + Na] + 506.2267; find 506.2214. NMR 3 Η (400 MHz, CDC1 3 ) δ 7.54 -7.23 (m, 10H, vs- Ar), 4.84 (s, 2H, CH 2 Ph), 4.67, 4, 60 (d, J = 12 .0 Hz, 1H, CH 2 Ph), 4 , 34 (d, J = 8.0 Hz, 1H, H- -1), 4.24-4 , 12 (m, 2H, H-3, H-4) , 4.05-4.03 (m, 1H, OCH 2a ) , 3.96 (t, J = 5, 9 Hz, 1H, H-6 a ), 3.86-3.79 (m, 2H, H-5, H-6 b ), 3, 68-3, 64 (m, 1H, OCH 2b ), 3.49-3.39 (m, 3H, CH 2 N 3 , H-2), 2.04-1.83 (m, 2H, CH 2 CH 2 N 3 ), 1.41, 1 , 37 (2 x s, 3H each, 2 x CH 3 ) • BE2017 / 5163 13 C NMR (101 MHz, CDC1 3 ) δ 12 8.50-127, 62 (C-Ar, C (CH 3 ) 2 ), 102.81 (Cl), 79, 59 (C-2), 79, 06 (C-4), 73.81 (C-3), 73.58 (CH 2 Ph) , 73.55 (CH 2 Ph), 72.24 (C-5), 69.51 (C-6), 66, 37 (OCH 2 ), 48.33 (CH 2 N 3 ), 29, 22 ( CH 2 CH 2 N 3 ), 27.79, 26, 33 (2 x CH 3 ). >]: iï « 4-O-Acetyl-2,6-O-benzyl-ß-D-galactopyranoside of 3-azidopropyl 21 Compound 20 (2.75 g, 5.7 mmol) was suspended in a 4/1 mixture of AcOH / H 2 O (50 ml). The reaction was warmed to 70 ° C for 2 h, when the TLC (7/3 mixture of cyclohexane / EtOAc) showed the disappearance of the starting material and the formation of a spot with a lower Rf. The solvent was removed at reduced pressure and the crude product was purified by flash chromatography (cyclohexane / EtOAc) to produce 2,6-O-benzyl-ß-D-galactopyranoside of 3-azidopropyl in a yield of 92% under the form of an oil (2.30 g). HR ESI-MS m / z C 23 H 29 N 3 O 6 [M + Na] + 446, 1954; found 446.1954. 3 H NMR (400 MHz, CDC1 3 ) δ 7.43-7.19 (m, 10H, H-Ar) 4, 89, 4, 67 (2 x d, J = 11.5 Hz, 1H, CH 2 Ph), 4.56 (s, IH CH 2 Ph), 4.33 (d, J = 7.6 Hz, IH, H-1), 4.06-3.89 (m, 2H H-4, OCH 2a ), 3.74 (m, 2H, 2 x H-6), 3.60 (m, 3H, H-3 , H 5, OCH 2b ), 3.49 (m, IH, H-2 ), 3.38 (t, J = 6.8 Hz, 2H CH 2 N 3 ), 1, 92-1, 88 (m, 2H, CH 2 CH 2 N 3 ). BE2017 / 5163 13 C NMR (101 MHz, CDC1 3 ) δ 13 8.44-127, 67 (C-Ar), 103, 60 (Cl), 79, 30 (C-2), 74, 67 (CH 2 Ph), 73, 60 (CH 2 Ph), 73.37 (C-5), 73.15 (C-3), 69.36 (C-6), 68.99 (C-4), 66.39 (OCH 2 ), 48.31 (CH 2 N 3 ), 29.21 (CH 2 CH 2 N 3 ). The diol was dissolved in CH 3 CN (30 ml), then triethyl orthoacetate (2.8 ml, 15.6 mmol) and PTSA (208 mg, 1.04 mmol) were added. The reaction was stirred at RT for 4 h (TLC, 6/4 mixture of cyclohexane / EtOAc), then the solvent was removed under reduced pressure. The crude product was dissolved in a 4/1 mixture of AcOH / H 2 O (50 ml) and after 2 h the mixture was concentrated. The crude product was purified by flash chromatography (cyclohexane / EtOAc) to give compound 21 in a yield of 87% (2.20 g) in the form of a pale yellow oil. HR ESI-MS m / z C 2 sH 31 N 3 O7 [M + Na] + 508.2060; found 508.2072. 3 H NMR (400 MHz, CDC1 3 ) δ 7.38-7.28 (m, 10H, H-Ar), 5.38 (dd, J = 3.6, 0.8 Hz, H-4), 4.94, 4.71 (2 x d, J = 10.9 Hz, 2H, CH 2 Ph), 4.58, 4.48 (2 x d, J = 11.9 Hz, 2H, CH 2 Ph), 4.41 (d, J = 7.8 Hz, 1H , H-l), 4.12- -4.09 (m, 1H, H-6 a ), 4.07-4.01 (m, 1H, OCH 2a ) , 3.79-3.76 (m, 2H, H-5, H-6 b ), 3.69-3.67 (m, 1H, OCH 2b ) , 3.61-3.49 (m, 1H, H-2, H-3), 3.42 (t, J = 6, 6 Hz, 2H, CH 2 N 3 ), 2.09 (s, 3H, CH 3 ), 1.95-1.90 (m, 2H, CH 2 CH 2 N 3 ). 13 C NMR (101 MHz, CDC1 3 ) δ 171.26 (CO), 138.27127.78 (C-Ar), 103, 88 (Cl), 79, 37 (C-2), 74, 93 (CH 2 Ph), 73, 64 (CH 2 Ph), 72.46 (C-5 ), 71, 94 (C-3; I, 68.48 (C-6), 68.06 (C-4), 64, 99 (OCH 2 ), 48.30 (CH 2 N 3 ), 2 9.19 (CH 2 CH 2 N 3 ), 21.07 (CH 3 ). BE2017 / 5163 Phenylthio-4,6-0-naphthylidene-2-deoxy-2phthalimido-glucopyranoside 23 Protected phenylthio-glucosamine 22 (5 g, 13.1 mmol) was deacetylated by overnight treatment with NaOMe in MeOH to pH 9-10. The mixture was neutralized with Dowex H +, then it was filtered. The filtrate was concentrated and dissolved in CH 3 CN (20 ml) to which freshly prepared naphthyl benzaldehyde dimethyl acetal (5 equivalents) and PTSA (0.2 equivalent) were added. After stirring overnight, the crude mixture was purified on silica gel (cyclohexane-EtOAc) to give 3.5 g of product, which was used directly for benzylation. To a solution of 3-OH sugar (3.7 g, 9.4 mmol) in DMF (20 ml), 60% NaH in mineral oil (587 mg, 14.1 mmol) was added at 0 ° C under a nitrogen atmosphere. After stirring for 20 min, BnBr (3.3 ml, 28.5 mmol) was added and the mixture was stirred overnight. The crude mixture was partitioned into water (x 3), and the combined organic phases were concentrated and purified on silica gel (cyclohexane-EtOAc) to provide monosaccharide 23 (5.3 g) as a white solid (yield of 69% over three stages). HR ESI-MS m / z C 3 gH 31 NC> 6S [M + Na] + 626.1613; found 626.1607. NMR A (400 MHz, CDC1 3 ) δ 7.78-6.77 (m, 21H, H-Ar), 5.70 (s, 1H, CHNap), 5.58 (d, J = 10.5 Hz, H-l), 4.70, BE2017 / 5163 4.42 (2 x d, J = = 12 , 3 Hz, 2H, CH 2 Ph), 4.41-4.32 (m, 2H, H-3, H-6 a ) , 4.24 (t, J = 10.0 Hz, H-2), 3.82 (t, J = 10.1 Hz, H-6 b ), 3.79 (t, J = 8.9 Hz, H, 4), 3.72-3.65 (m, 1H, H-5). 13 C NMR (101 MHz, CDC1 3 ) δ 167.82 (CO), 137.70123.40 (C-Ar), 101.53 (CHNap), 84.16 (Cl), 82.93 (C-4 ), 75.46 (C-3), 74.23 (CH 2 Ph), 70.44 (C-5), 68.77 (C-6), 54.75 (C-2). 3-O-Benzyl-4,6-0-naphthylidene-2-deoxy-2phthalimido-glucopyranosyl- (1 ^ 3) -4-O-acetyl-2, 6-di-Obenzyl-ß-D-galactopyranoside 3- azidopropyl 24 A solution of donor 23 (800 mg, 1.27 mmol) and acceptor 21 (514 mg, 1.05 mmol) with activated molecular sieves (4 Â, 1.2 g) in DCM (12 ml) was stirred for 20 min under nitrogen. NIS (570 mg, 2.54 mmol) and TfOH (22 μΐ, 0.254 mmol) were added at -20 ° C. After stirring for 3 h (TLC, 7/3 mixture of toluene / EtOAc), the reaction mixture was neutralized with TEA, the solid was separated by filtration and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography (toluene / EtOAc) to give compound 24 in a yield of 72% (760 mg) in the form of a yellow oil. HR ESI-MS m / z Ο57Η 5 6Ν 4 Οι 3 [M + Na] + 1027.3742; found 1027.3769. BE2017 / 5163 3 H NMR (400 MHz, CDC1 3 ) δ 8.15-6.71 (m, 26H, H-Ar), 5.81 (s, 1H, CHNap), 5.46 (d, J = 8.3 Hz, 1H, H-1 B ), 5.42 (d, J = 3.3 Hz, 1H, H-4 A ), 4.83 (t, J = 11.4 Hz, 2H, 2 x CHHPh), 4.69-4.33 (m, 5H, 4 x CHHPh, H-3 B ), 4.26 (d , J = 8.0 Hz, 1H, H-1 A ), 4.22 (dd, J = 7.9, 10.2 Hz, 1H, H-2 B ), 3, 97-3, 80 (m , 5H, 2 x H-6 A ' B , OCH 2a ), 3.74 (dd, J = 9.6, 3.4 Hz, 1H, H-3 A ), 3.72-3, 60 (m, 1H, H-5 A ), 3.58-3.42 (m, 4H, OCH2b, H-5 B , H-2 A , H-4 B ), 3.18 (dd, J = 10.1, 6.4 Hz, 2H, CH2N 3 ), 2.14 (s, 3H, CH 3 CO), 1.75 -1.69 (m, 2H, CH 2 CH 2 N 3 ). 13 C NMR (101 MHz, CDC1 3 ) δ 171.48, 167.38 (CO), 134.00-123, 16 (C-Ar), 103.47 (C-1 B ), 101.60 (CHNap), 99, 07 (C-1 A ), 82, 91, 82.73, 78, 71, 78.39, 74.50, 74.35, 74.30, 74.20, 74, 01, 73, 67, 72.76, 69, 72 (C-4 A ), 69, 03, 68.71 (2xC-6), 68.55 (OCH2), 56, 07 (C-2 B ), 48.05 (CH2N 3 ), 28, 99 (CH 2 CH 2 N 3 ), 20.89 (CH 3 CO). 3-O-Benzyl-4-0- (2-naphthyl) methylene-2-deoxy-2phthalimido-glucopyranosyl- (1 ^ 3) -4-O-acetyl-2,6-di-Obenzyl-ß-D-galactopyranoside of 3-azidopropyl 25 Disaccharide 24 (760 mg, 0.75 mmol) has been dissolved in CH 3 CN (15 ml). The solution at summer cooled at 0 ° C and the BH 3 -NMe 3 complex (275 mg, 3.75 mmo1) and of BF 3 Et 2 O (470 μΐ, 3.75 mmol) have summer added. The solution a been restless for 6 a.m. in now the temperature at 0 ° C (TLC, mixture 7/3 of toluene / EtAOc), then the reaction was neutralized by BE2017 / 5163 the addition of TEA and MeOH. The solvent was removed under reduced pressure and the crude product was purified by flash chromatography (toluene / EtOAc) to give compound 25 in a yield of 64% (483 mg, 0.48 mmol) as an oil yellow. HR ESI-MS m / z C57H58N4O13 [M + Na] + 1029.3898; found 1029.3902. 3 H NMR (400 MHz, CDC1 3 ) δ 7, 86-7.37 (m, 26H, H-Ar), 5.64 (d, J = 3.4 Hz, 1H, H-4 A ), 5.41 (d, J = 8.5 Hz, 1H, H-1 B ), 5, 04, 4, 92 (2 d, J = 11.1 Hz, 2H, CH 2 Ar), 4,864.73 (m, 2H, 2 CHHPh), 4.48-4.25 (m, 5H, 4 CHHPh, H-3 B ), 4.21 (d, J = 9.0 Hz, 1H, H-1 A ), 4.18 (dd, J = 8, 0, 10.1 Hz, 1H, H-2 B ), 4.06- 3.88 (m, 2H, 2 x H-6a A ' B ), 3.87-3, 82 (m, 1H, OCH2a), 3.72 (t, J = 9.0 Hz, 2H, H- 6b A ' B ), 3.69-3.67 (m, 1H, OCH2b), 3.50-3.34 (m, 5H, H-2 A , H-3 A , H-4 B , H5 A ' B ), 3.17-2.98 (m, 2H, CH2N 3 ), 2.08 (s, 3H, CH 3 CO), 1,721.65 (m, 2H, CH 2 CH 2 N 3 ). 13 C NMR (101 MHz, CDC1 3 ) δ 171.51, 167.42 (CO), 134 , 11-123.13 (C-Ar), 103.44 (C-1 B ), 99.56 (C-1 A ), 81.11, 79, 15, 78.77, 78.42, 77.79, 77.23, 75.71, 75.20, 74, 89, 73, 76, 73.38, (4 x CH 2 Ar), 72.38, 69, 92 (C-4 A ), 68.08, 68, 81 (2 x C-6), 61.50 (OCH 2 ) , 56.11 (C-2 B ) , 48.01 (CH 2 N 3 ) 28, 96 (CH 2 CH 2 N 3 ), 21.23 (CH 3 CO). 2-O-Acetyl-3,4,6-tri-O-benzyl-ß-D-glucopyranosyl (1 ^ 6) -3-O-benzyl-4-O- (2-naphthyl) methylene-2-deoxy- 262 BE2017 / 5163 3-azidopropyl phthalimido-ß-D-glucopyranosyl- (1 ^ 3) -4-O-acetyl-2,6-diO-benzyl-ß-D-galactopyranoside 27 A solution of compounds 25 (483 mg, 0.48 mmol) and 26 (413 mg, 0.62 mmol) with activated molecular sieves (4 Â, 800 mg) in DCM (8 ml) was stirred for 20 min under nitrogen. TMSOTf (23 μΐ, 0.12 mmol) was added at -10 ° C. After stirring the reaction mixture for 12 h at RT, TEA was added until neutral pH, the solid was separated by filtration and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography (8/2 toluene / EtOAc mixture) to give compound 27 in a yield of 72% (504 mg). HR ESI-MS m / z C86H88N4O19 [M + Na] + 1503, 5940; found 1503.5855. 3 H NMR (400 MHz, CDC1 3 ) δ 7.76-6.55 (m, 41H, H-Ar), 5.42 (d, J = 3.2 Hz, 1H, H-4 A ), 5.34 (d, J = 8.3 Hz, 1H, H-1 B ), 5.06 (t, J = 8.8 Hz, 1H, H-2 C ), 4.97-4.72 (m, 5H, 5 x CHHPh), 4.65 (d, J = 12.5 Hz, 1H, CHHPh), 4, 60-4 , 39 (m, 9H, 8 x CHHPh, Hl c ), r 3, 88-3.64 (m, 9H), 3.583 , 30 (m, 9H), 3.26-3.09 (m, 3H, y understood, 3, 10, CH 2 N 3 ), > 2, 65, 2.10 (2 x s, 3H each , 2 x CH 3 CO), 1.82-1.71 (m, 2H, CH 2 CH 2 N 3 ). 13 C NMR (101 MHz, CDC1 3 ) δ 171.38, 170.37, 169, 72, 169, 49 (C = O), 133.59-123, 10 (C-Ar), 103.54 (C -1 A ), 101.34 (Cl c ), 98.56 (C-1 B ), 82.88, 79, 94, 79, 07, 78, 64, 78.07, 77.60, 77.23, 75.25, 74.92, 74.74, 74.10, 73.69, 73.47 (7 x CH 2 Ar), 72.21, 69, 78 (C-4 A ), 68, 68, 68.53, 68, 04 (3 x C-6), 66.71 (OCH 2 ), 56, 26 (C-2 B ), 48, 09 (CH 2 N 3 ), 29, 03 (CH 2 CH 2 N 3 ), 22.28, 22.10 (2 x CH 3 CO). BE2017 / 5163 2-O-Acetyl-3,4,6-tri-O-benzyl-ß-D-glucopyranosyl (U6) -3-0-benzyl-2-däsoxy-2-phthalimido-ß-D-glucopyranosyl- (IAS) -4-O-acetyl-2,6-di-O-benzyl-ß-D-galactopyranoside of 3-azidopropyl 28 To a solution of compound 27 (504 mg, 0.34 mmol) in a 4/1 mixture of DCM / CH3OH (12 ml), DDQ (235 mg, 1.02 mmol) was added. The reaction mixture was stirred at RT for 5 h (TLC, 7/3 mixture of cyclohexane / EtOAc), then it was diluted with DCM and shared with aqueous NaHCO 3 . The aqueous phase was extracted 3 times with 20 ml of DCM, then the combined organic phases were dried with Na 2 SO 4 and evaporated under reduced pressure. The crude product was purified by flash chromatography (cyclohexane / EtOAc) to give compound 28 in the form of a yellow oil in a yield of 85% (390 mg, 0.29 mmol). HR ESIMS m / z C 8 6H84N 4 O 19 [M + H] + 1341.5495; found 1341.5532. 4 H NMR (400 MHz, CDC1 3 ) δ 7.76-6.55 (m, 34H, H-Ar), 5.36 (m, 2H, H-1 B , H-4 A ), 5.07 (t, J = 8.2 Hz, 1H, H-2 C ), 4.89-4.75 (m, 3H, 3 x CHHPh), 4.71-4.41 (m, 8H, CHHPh, including d, 4.66, d, J = 7.9 Hz, Hl c ), 4.24-4, 09 (m, 4H, H-6a A / c , 2 x CHHPh, including, 4.12, d, J = 7.0 Hz, H-1 A ), 4.03-3.61 (m, 10H), 3, 59-3, 67 (m, 7H), 3.15-3.09 (m, 2H, CH 2 N 3 ), 2, 02, 2.00 (2 xs, 3H each, 2 x CH 3 CO), 1.73-1.66 (m, 2H, CH 2 CH 2 N 3 ). 13 C NMR (101 MHz, CDC1 3 ) δ 171.40, 170.35, 169, 72, BE2017 / 5163 169.56 (C = O), 138.42-123.08 (C-Ar), 103.46 (C-1 A ), 100.42 (C-1 C ), 98.38 (C-1 B ), 82.70, 78.49, 78.29, 77.91, 75.03, 74.78, 74.23, 74.17, 74.07, 73.88, 73.71, 73.57, 73.53, 72.80 (6 X CH 2 Ph), 72.54, 72.26, 69.65 (C —4 A ), 69.12, 68.20, 67, 96 (3 x C-6), 66, 76 (OCH 2 ), 55 , 72 (C- 2 B ), 48, 07 (CH 2 N 3 ), 29, 23 (CH 2 CH 2 N 3 ), 20, 96, 20.77 (2 x CH 3 CO). O- [4,7,8,9-Tetra-O-acetyl-5- (N-acetamido) -3,5dideoxy-D-glycero-aD-galacto-non-2-ulopyranosylonate] - (2 ^ 3 ) -O- (2,4,6-tri-O-benzoyl-ß-D-galactopyranosyl) - (1 ^ 4) - [(2-O-acetyl-3,4,6-tri-O-benzyl- ß-Dglucopyranosyl) - (1 ^ 6)] - 3-0-benzyl-2-deoxy-2phthalimido-ß-D-glucopyranosyl- (1 ^ 3) -4-O-acetyl-2,6-diO-benzyl- 3-azidopropyl ß-D-galactopyranoside 29 A solution of trisaccharide 28 (390 mg, 0.29 mmol) and donor disaccharide (329 mg, 0.29 mmol) with activated molecular sieves (4 Â, 700 mg) in DCM (8 ml) was stirred for 20 min under nitrogen. TMSOTf (11 μΐ, 0.058 mmol) was added at -10 ° C. After stirring the reaction mixture for 10 h at RT, followed by TLC (7/3 mixture of toluene / acetone), TEA was added until neutral pH, the solid was separated BE2017 / 5163 by filtration and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography (toluene / acetone) to give compound 29 in a yield of 65% (430 mg) in the form of a foam. HR ESI-MS m / z C122H129N3O39 [M + Na] + 2310.8162; found 2310.8175. 3 H NMR (400 MHz, CDCI3) δ 8.10-6.62 (m, 49H, H-Ar), 5.59-5, 56 (m, 1 H, H-8 E ), 5.41 (dd, J = 7.8, 9.2 Hz, 1H, H-2 D ), 5.29-5, 27 (s, 2H, H-7 E , NH), 5.18 (dd, J = 2.3, 9.4 Hz, 1H, H-3 D ), 5.13 (d, J = 8.3 Hz, 1H, H-1 B ), 5.02 (d, J = 7.8 Hz, 1H, H -1 D ), 4.92-4.88 (m, 2H, H-4 A , H-4 D ), 4.87-4.57 (m, 7H), 4.51-4.25 (m , 9H, including d, 4.46, J = 7.8 Hz, Hl c , and d, 4.26, J = 9.0 Hz, H-1 A ), 4.153.94 (m, 8H), 3.81-3.57 (m, 13H , including s, 3.74, COOCH3), 3.53 (dd, J = 2.3, 10.8 Hz, 1H), 3.47-3.26 (m, 5H), 3.19 (t, J = 8.2 Hz, 1H ), 3.07-3, 02 (m, 2H, CH 2 N 3 ), 2.45 (dd, J = 12.5, 4.4 Hz, 1H, H-3 e E ), 2.11, 1, 96, 1.85, 1.83, 1.70 (5 xs, 3H each, 6 x CH 3 CO), 1.64-1.53 (m, 3H, H-3 a E , CH2CH2N3), 1.35, 1.18 (2 xs, 3H each, 2 x CH3CO). 13 C NMR (101 MHz ,, CDCI3) δ 17i 0.73, 17 0.55, 170.27, 170 , 21, 169, 96, 169, 13, 168, 12, 16 7.77, 16 , 5.71, 165.55, 165 , 12 (C = O), 138, 55-122.99 (C- Ar), 103.41 (C-1 A ), 101 , 54 (Cl c ), 101.00 (C-1 D ), 98.45 (C-1 B ), 96.91, 82.61, 79, 17, 78.55, 78.18, 77.73, 76, 82, 75.00, 74.82, 74.75, 74, 62, 74.50, 74.02, 73.58, 73.48, 73.31, 72.48, 71.85, 71, 80, 71, 65, 70, 67, 69, 91, 69, 37, 68.77, 68.68, 68.23, 67, 93, 67, 61, 66, 61, 66.20, 62.10, 61.59 (4 x C-6) , 56.11 (VS- 2 B ), 53, 09 (C-5 E ), 48, 87 (COOCH3) .48.05 (CH2N3) , 37.26 (C-3 C ), 28, 97 (CH2CH2N3), 23, 15, 21.43, 21.08, 20, 80, 20.75, 20.71, 20.24 (7 x CH 3 CO). BE2017 / 5163 Example 8 Final Deprotection of the Oligosaccharides and of the Compounds 12, 18 and 29 A mixture of protected pentasaccharide (0.1 mmol) and Lil (3 mmol) in pyridine (5 ml) was heated for 24 h at 120 ° C. The reaction mixture was concentrated in vacuo, and the residue was purified by column chromatography on silica gel (gradient of 2% MeOH in DCM) to give the demethylated product. This material was dissolved in ethanol (4 ml), and ethylenediamine (400 ml) was added. After stirring for 16 h at 90 ° C, the reaction mixture was then concentrated in vacuo, and the residue was coevaporated from toluene (2 x 10 ml) and EtOH (2x5 ml). The crude mixture was redissolved in pyridine (5 ml), and acetic anhydride (5 ml) was added. After stirring for 16 h at room temperature, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in MeOH and MeONa was added until pH = 13. After 48 h, the reaction was neutralized and the solvent was removed in vacuo. The residue was dissolved in MeOH and Pd / C (1/1 w / w based on sugar) was added. The reaction mixture was stirred under H 2 pressure (3 bar) for 72 h. Then, the catalyst was filtered off and the filtrate was concentrated under reduced pressure. The reaction mixture was purified by exclusion chromatography on a G-10 column using water for elution. The sugar-containing fractions were quantified by assaying sialic acid and freeze-dried to give the BE2017 / 5163 deprotected oligosaccharide compounds 1 to 3 in the form of an amorphous powder (yield 31 to 55%). O- [5-N-Acetamido-3,5-dideoxy-D-glycero-a-Dgalacto-non-2-ulopyranosyl- (2 ^ 3) -O- (ß-D-galactopyranosyl) - (1 ^ 4) -0-2-ac0tamido-2-d0soxy-ß-D-glucopyranosyl- (1 ^ 3) -O-ß-D-galactopyranosyl) - (1 ^ 4) -O-ß-Dglucopyranoside of 3-aminoopropyl 1 HR ESI-MS m / z C 4 oH 6 9N 3 0 9 [M + H] + 1056, 3971; find 1056.3966. O- [5-N-Acetamido-3,5-dideoxy-D-glycero-a-Dgalacto-non-2-ulopyranosyl- (2 ^ 3) -O- (ß-D-galactopyranosyl) - (1 ^ 4) -O - [(ß-D-glucopyranosyl) (1 ^ 6)] - 0-2ac0tamido-2-d0soxy-ß-D-glucopyranosyl- (1 ^ 3) -O-ß-Dgalactopyranoside of 3-aminoopropyl 2 HR ESI-MS m / z C 40 H 69 N 3 O 9 [M + Na] + 1078.3810; find 1078.3810. O- [5-N-Acetamido-3,5-dideoxy-D-glycero-a-Dgalacto-non-2-ulopyranosyl- (2 ^ 3) -O- (ß-D-galactopyranosyl) - (1 ^ 4) -O - [(ß-D-galactopyranosyl) - (1 ^ 4) -Ο- (ßD-glucopyranosyl) - (1 ^ 6)] - 0-2-ac0tamido-2-d0soxy-ß-Dglucopyranoside 3-aminoopropyl 3 HR ESI-MS m / z C 40 H 69 N 3 O 9 [M + H] + 1056, 3969; find 1056.3966. The NMR spectra of compounds 1 to 3 are reported in Table 2 below: Table 2 3 H and 13 C NMR signals (ppm) of compounds 1 to 3 in D 2 O a Compound 2 Compound 1 Compound 3 Residue m 13 C m 13 C 3 H 13 C Gai î 4.45 103.28 4.43 103.77 4.39 103.72 BE2017 / 5163 J 7.8 Hz J 8.2 Hz J 8.0 Hz 2 3.55 71.58 3.57 70, 68 3.57 70.49 3 3, 68 73, 18 3, 72 82, 85 3, 72 83, 08 4 3, 93 6 9.48 4.16 6 9.05 4.16 6 9.16 5 3, 68 72, 96 3, 66 75, 10 3, 69 75, 70 6 3, 71 61.58 3, 65 63.16 3, 73 62.35 6 ' 3.76 3, 88 3.76 4.52 4.69 4, 71 1 101.98 103.72 103.63 J 7.8 Hz J 8.2 Hz J 8.0 Hz 2 3, 75 5 5.68 3, 81 55.89 3.80 56, 08 3 3, 72 74.23 3, 73 72, 82 3, 73 73.40 GlcNAc 4 3.86 77, 98 3.76 78.50 3, 88 78.28 5 3, 72 76, 02 3, 72 7 5.69 3, 73 74.38 6 4.00 68, 18 3, 95 68, 18 3, 97 68.51 6 ' 4.31 3, 95 4.30 4.55 4.50 4.52 1 103.00 102.74 103.66 J 7.8 Hz J 8.5 Hz J 8.0 Hz 2 3.37 73.35 3.32 73.51 3.31 73, 88 3 3, 67 75, 15 3, 64 75.38 3.52 76, 78 Glc 4 3, 67 78, 75 3, 65 78.58 3.40 70, 78 5 3, 68 75.54 3, 66 75.38 3.53 76.58 6 3, 84 60, 73 3, 81 60, 62 3, 73 61.38 6 ' 3.99 3, 96 3, 93 4, 61 4.56 4, 62 1 102.78 103.00 102.95 J 7.6 Hz J 9.0 Hz J 7.8 Hz 2 3.56 69, 89 3.57 70.22 3.57 70.28 3 4, 10 75, 93 4, 12 76, 18 4, 10 76.48 Gay 4 3, 96 68.27 3, 92 68, 78 3, 97 68.40 5 3, 67 75.33 3, 71 75.56 3.70 76, 08 6 3, 71 61, 80 3, 74 61.85 3, 73 61, 78 6 ' 3, 75 3, 71 3.76 3 2.76 40.36 2.76 40.35 2.76 40.38 3 ' 1.83 1.80 1.82 4 3, 67 69.30 3, 68 6 9.05 3, 68 69.38 5 3, 85 52.34 3, 85 52.36 3, 85 52.58 NeuNAc 6 3, 63 73, 60 3, 62 73, 70 3, 64 74, 05 7 3.60 6 9.05 3, 65 68, 78 3.60 69.25 8 3, 87 72.45 3, 87 72.59 3, 88 72, 70 9 3.86 63, 18 3, 88 63.27 3, 87 3.54 9 ' 3, 66 3, 65 3, 66 at. The NMR experiments were carried out on a Bruker 500 MHz NMR instrument equipped with a TBI probe cooled to controlled temperature (± 0.1 ° C). Data acquisition and processing was done using TOPSPIN ™ 1.3 and 3.1 software, respectively. b. Gais refers to the residue linked to NeuNAc BE2017 / 5163 Conjugation to CRM 197 A solution of SIDEA (10 equivalents) and TEA (0.2 equivalents) in DMSO was added to pentasaccharide 13. The reaction was stirred for 3 h, then the product was precipitated at 0 ° C by addition of ethyl acetate (9 volumes). The solid was washed 10 times with ethyl acetate (2 volumes each time) and lyophilized. Activated sugar was conjugated to CRM 19 7 in 100 mM NaPi at a protein concentration of 5 mg / ml, using a ratio of 50 to 100/1 mol of saccharide / mol of protein. EXAMPLE 9 Conjugation of Semisynthetic PSIII Oligosaccharides to a Support Protein For the conjugation reaction to CRM 197 , purified oligosaccharides from chemical depolymerization were dissolved in 100 mM sodium phosphate buffer at pH 7.2. CRM 197 was added to the solution in an active ester to protein molar ratio varying from 10/1 to 70/1 and a final protein concentration of 10 mg / ml. Then, NaBCNH 3 was added to the solution (saccharide / NaBCNH 3 , 1/1, w / w) and incubated overnight at 37 ° C. Conjugation was followed by SDS-PAGE with 4 to 12% polyacrylamide in MOPS. The conjugates were purified from the unreacted saccharide on a hydroxyapatite CHT column, using for elution 2 mM sodium phosphate / 300 mM NaCl at pH 7.2 (20 ml, 1 ml / min), followed by 400 mM sodium phosphate at pH 7.2 (40 ml, 1 ml / min). When CRM 197 which had BE2017 / 5163 unreacted was present, the conjugate was purified by chromatography on a hydroxyapatite CHT column using a 4-step elution program: 2 mM sodium phosphate / 300 mM NaCl at pH 7.2 (20 ml, 1 ml / min), 10 mM sodium phosphate at pH 7.2 (20 ml, 1 ml / min), 35 mM sodium phosphate at pH 7.2 (20 ml, 1 ml / min), and 400 mM sodium phosphate at pH 7.2 (40 ml, 1 ml / min). The conjugate was detected by measuring the UV absorption at 215, 254 and 280 nm. The protein content in the purified glycoconjugates was determined by micro-BCA (Thermo-scientific). The saccharide content was estimated by an HPAEC-PAD analysis. The MALDI TOF spectra of the conjugated oligosaccharides are provided in FIG. 8A (conjugates of the synthetic fragments 1 to 3) and 8B (conjugates of the oligosaccharides), where GD indicates the degree of glycosylation. Table 3 Physico-chemical characteristics of the glycoconjugates prepared Concentrationin protein(pg / ml) Concentrationin saccharide(pg / ml) Degree ofglycosylation(mol / mol) CRM-f ragrasynthetic III 1 1428 75 30 CRM-f ragrasynthetic III 2 1268 64 30 CRM-f ragrasynthetic III 2 1035 409 23.0 CRM-f ragrasynthetic III 3 1518 700 27.0 CRM-III DP2 1122 140 3.5 BE2017 / 5163 CRM-III DP2 535 160 9, 0 CRM-III DP3 383 44 2.0 CRM-III DP3 484 130 4.5 CRM-III DP5 639 159 30 CRM-III DP5 349 161 5.5 CRM-III DP6.5 456 79 1.5 CRM-III DP6.5 289 110 3.5 CRM-III DP11 531 235 2.5 CRM-III PSIII 725 836 0.4 Example 10 Immunogenicity of the Conjugates in Mice Two groups of eight female BALB / c mice were immunized by intraperitoneal injection of 0.5 µg saccharide content of each glycoconjugate formulated with 400 µg aluminum hydroxide as an adjuvant. Aluminum hydroxide and CRM-PSIII were used as controls. The mice received the vaccines on days 1, 21 and 35. The sera were collected on days 1, 21, 35 and 49. ELISA analysis: the titles of the indirect ELISA (enzymelinked immunosorbent assay) test of the PS-specific IgGs were determined using HSA-PSIII as sensitization reagent. Microtiter plates (NUNC Maxisorp; Nalge Nunc International Corp., Rochester, NY) have the addition of 100 µl by sensitization (1 µg / ml) in PBS IX at pH 7.2. The plates were incubated overnight at 4 ° C and were washed with PBS containing 0.05% Tween 20 (PBS-T) and then blocked with 2% bovine serum albumin in PBS-T for 1.5 h at 37 ° C. The wells were sensitized with reagent wells then filled with 100 μl of serum diluted in PBS72 BE2017 / 5163 T + 2% BSA and incubated at 37 ° C for 1 h. After 3 washes, 100 μΐ / well of anti-mouse IgG-alkaline phosphatase or anti-rabbit IgG-alkaline phosphatase diluted in PBST + 2% BSA were added (SigmaAldrich) and the plates were incubated for 1 , 5 h at 37 ° C. The plates were again washed 3 times with PBS-T, and finally 100 μΐ of peroxidase substrate (4 mg / ml in diethanolamine pH 9.8) were added to each well, this followed by incubation of the plates for 30 min at RT. The reaction was neutralized by the addition of 100 μΐ of a 7% EDTA solution and the plates were read immediately at 405 nm. Competition ELISA test: competition inhibition tests were carried out by following the ELISA procedure as described above with the following modifications. After the blocking step, using a polypropylene microtiter plate with weak bond (NUNC), the PS III or its fragments were diluted in dilution buffer (PBS-T + 2% of BSA) with a step of half-beginner dilution from 2 mg / ml. Then, the same volume of mAb at a fixed concentration was added to the wells and the reaction was allowed to interact for 20 min at RT. After a slight mixing, the reaction was transferred (100 μΐ / well) to the sensitized and saturated plates and incubated for 1 hour at 37 ° C. The rest of the procedure was followed as described above. Opsonophagocytosis destruction test (OPKA): the functional activity of the sera was determined in an OPKA test. HL-60 cells were cultured BE2017 / 5163 in RPMI 164 0 with 20% fetal calf serum. Incubation was carried out at 37 ° C with 5% CO 2 . The HL-60 cells differentiated into neutrophils with 0.78% DMF and after 4 to 5 days, they were used as a source of phagocytes. Sera diluted serially in red HBSS were mixed with 6 x 10 4 CFU per well of the GBS strain of serotype III COH1. HL-60 cells (2 x 10 6 cells / well) and rabbit complement (diluted 2% in water) were added and incubated at 37 ° C for 1 h with shaking. Before (T0) and after (T60) incubation, the mixtures were diluted and plagued on blood agar plagues (Becton-Dickinson). Chague plague was then incubated overnight at 37 ° C with 5% CO 2 , CFU count the next day. The OPA titer was expressed as the inverse of the dilution of serum leading to 50% destruction of bacteria, and the percentage of destruction is calculated as follows:% destruction = (T0 - T60) / T0 where T0 represents the average of the CFU counted at T0, and T60 represents the average of the CFU counted at T60 for the two replicates of each dilution of serum. Surface plasmonigue resonance analysis (RPS): kinetics and binding affinities were determined by RPS using a BIACORE X100 system. The glycoconjugates of PSIII and its fragments were immobilized on CM5 research quality sensor chips (Biacore) using the amine coupling kit supplied by the manufacturer (Biacore). The immobilizations were carried out in 10 mM sodium acetate (pH 4.5) at concentrations of conjugates of BE2017 / 5163 mg / ml. The immobilized surface density was -250 resonance units in each case. The measurements were carried out in 10 mM HEPES (pH 7.2), 150 mM NaCl, 3 mM EDTA, 0.005% Tween 20 at 25 ° C and at a flow rate of 45 μΐ / min. Following the binding of mAb or Fab, the surfaces of the conjugates were regenerated with 3.5 M MgCl 2 and a contact time of 120 s. Sensorgram data was analyzed using BIAevaluation software (Biacore). Inhibition of Fab binding by RPS: inhibition tests were carried out following the RPS procedure as described above using a CM5 sensor chip with immobilized HSA-PSIII. The analysis of the binding was carried out with samples of Fab at a fixed concentration preincubated with PSIII or its fragments diluted in series (2x) starting from a concentration of 2 mg / ml. Results The data show that the conjugates of the invention comprising oligosaccharides provide equivalent or improved characteristics compared to the conjugates comprising full-length native capsular polysaccharides. The competitive ELISA experiments using the rabbit mAb NVS l-19-5m show the dependence on the length of the capacity of the polysaccharide to inhibit the binding to anti-PSIII protective mAbs (FIG. 9a). The inhibition of mAb binding increased slightly with the size of the DP2 PS at 13 to 1 log and was found to be 5 log higher when PSIII was used as an inhibitor. BE2017 / 5163 To exclude the effect of the interaction of bivalent IgG mAbs on avidity, a competitive RPS test was carried out in which oligosaccharide fragments (DPI range 13) were tested as competitors for the binding of the soluble Fab fragment to PSIII conjugated to human serum albumin (HSA) immobilized on the chip. Two major populations of inhibitors, DP> 2 and DP <2, were differentiated (Figure 9b). The DP> 2 oligosaccharides showed an asymptotic increase in affinity for native PSIII, with a difference of only 2 log between PSIII and DP2 (Figures 9A and 9B). This observation was corroborated by a difference less than a log of the K d for the interaction of the PSIII and of a rabbit protective Fab-HSA calculated by RPS (as it is shown in Table 4). These data suggest that the part involved in the binding is no different for the fragments with a DP> 2. 0 Table 4 Kinetic and affinity constants for the binding of Rabbit Fab with CRM conjugates k a (MV 1 ) k d (s' 1 ) K d (M) PSIII 1.4 x 10 5 (± 1.4) a 3, 6 x ΙΟ ' 3 (± 0.8) 2, 6 x ΙΟ ' 8 DP2 3.9 x 10 4 (± 1.4) 4.4 x ΙΟ ' 3 (± 6.1) 1.1 x ΙΟ ' 7 a The numbers in parentheses are the AND in% BE2017 / 5163 Example 11 ELISA Analysis of Mouse Immune Serum Using Synthetic Fragments as Sensitization Reagents The glycoconjugates derived from the synthetic fragments DPI 1 to 3 were used to measure by an ELISA test the specific antibodies present in the murine anti-PSIII serum produced by immunization with the native polysaccharide conjugated with a protein of the hair of GBS (FIG. 10). Conjugated compounds 2 and 3, showing a Glc ß- (1 ^ 6) residue bound to GlcNAc, displayed the highest binding. In contrast, the linear conjugated oligosaccharide 1 was recognized ~ 10 times less than 2 and 3, and only slightly better than the negative control CRM197. As expected, the highest level of anti-PSIII antibody was detected for the positive control PSIII-CRMxgv. In summary, these data indicated that the presence of branching is a relevant structural motif for the recognition of anti-PSIII antibodies. EXAMPLE 12 Analysis in vivo of oligosaccharide jues of different length (FIGS. 11A and B) The effect of chain length on the immunogenicity of PSIII glycoconjugates was tested in vivo. The mice were immunized with CRM197 conjugates of the different fragments. A booster was given after two weeks, followed by a second booster after three weeks. After the third immunization, the sera were examined for the anti-PSIII IgG content and their opsonophagocytic activity. BE2017 / 5163 The DP 2 conjugate was the shortest fragment triggering anti-PSIII antibodies (Figure 11A). A mouse gave anti-PSIII directed against the branched repeating unit (structure 2). This serum had modest functionality in the OPKA analysis. Fragments with PD> 3 induced anti-PSIII IgG at significantly higher rates compared to native full-length PSIII. The OPKA titers were 4 to 5 times higher than that of the native PSIII (Table 4 and Figure 11B). These data indicated that the fragments with a DP> 2 can be used to prepare effective anti-GBS serotype III vaccines, since they contain the minimum part that is necessary to raise protective antibodies. Table 5 Geometric mean and OPKA titles for sera derived from different conjugates Degree ofglycosylation(mol / mol) ELISA title(EU / ml)Averagegeometric(95% CI) Title OPKway CRM-f ragrasynthetic III 1 30 10 <30 CRM-f ragrasynthetic III 2 30 10 <30 CRM-f ragrasynthetic III 2 23.0 15 (10-29) <30 CRM-f ragrasynthetic III 3 27.0 - <30 CRM-III DP2 3.5 13 (10-19) <30 CRM-III DP2 9, 0 237 (101-556) 590 CRM-III DP3 2.0 61 (23-161) 176 BE2017 / 5163 CRM-III DP3 4, 5 1946 (953-3977) 1862 CRM-III DP5 3, 0 3124 (1780-5484) 2499 CRM-III DP5 5, 5 1179 (159-8771) 3321 CRM-III DP6.5 1, 5 540 (196-1484) 1250 CRM-III DP6.5 3, 5 2262 (1467-3490) 1501 CRM-III DP11 2, 5 756 (332-1723) 461 CRM-III PSIII 0, 4 517 (345-774) 484 For the shortest fragments (DP 2 and 3), a parameter which proved to be crucial for inducing good levels of functional antibodies was the saccharide / protein molar ratio. As shown in Figure 12, when this ratio was low (3.5 for DP 2 and 4.5 for DP 3), the glycoconjugates were ineffective However, when the saccharide / protein molar ratio was increased until at 9.0 and 4.5 mol of saccharide / mol of protein for DP2 and 3, respectively, the glycoconjugates have become comparable or superior to the full-length polysaccharide in terms of titers of both IgG and OPKA (FIGS. 12A and 12B, degree of glycosylation indicated in parentheses in the figures). While certain embodiments of the present invention have been described and illustrated specifically above, it is not intended that the invention is limited to such embodiments. Various modifications can be made without departing from the scope and spirit of this BE2017 / 5163 invention as presented in the following claims. BE2017 / 5163 References 1. Wessels et al. (1990) J Clin Invest 86: 1428- 2. Paoletti and al . (1992) Infect Immun 60: 4009- 3. Paoletti and al . (1992) J Clin Invest 89: 203- 4.1 7 Γ WesselsΊ - Δ and al. (1987) Proc Natl Acad Sel USA 1! 15. J 4.Wang and al. (2003) Vaccine 21: 1112-7. 6. Wessels and al. (1993). Infect Immun 61: 4760-6. 7. Wessels and al. (1995) J Infect Dis 171: 879- . 8. WO 2005/000346 9. Anonymous (Jan 2002) Research Disclosure, 453077. 10. Anderson (1983) Infect Immun 39 (1): 233-238. 11. Anderson et al. (1985) J Clin Invest 76 (1): 52-59. 12. EP-A-0372501 13. EP-A-0378881 14. EP-A-0427347 15. WO 93/17712 16. WO 94/03208 17. WO 98/58668 18. EP-A-0471177 19. WO 91/01146 20. Falugi et al. 21. Baraldo et al. 22. EP-A-0594610 (2001) Eur J Immunol 31 (2004) Infect Immun 72 3816488481 BE2017 / 5163 23. WO 00/56360 24. WO 02/091998 25. Kuo et al. (1995) Infect Immun 63: 2706-13. 26. WO 01/72337 27. WO 00/61761 28. WO 00/33882 29. WO 96/40242 30 . Lei et al. (2000) Dev Biol (Basel) 103: 259- 264. 31. WO 00/38711 ; US Patent 6,146 902. 32. Request of patent international PCT / IB2008 / 02690, 'CONJUGATE PURIFICATION ', claiming priority to GB-0713880.3 (NOVARTIS AG), published in WO 2009/010877. 33. WO 99/24578 34. WO 99/36544 35. WO 99/57280 36. WO 00/22430 37. Tettelin and al. (2000) Seien, oe 287: 18C ) 9-1815. 38. WO 96/29412 39. Pizza et al. (2000) Science 287: 1816- 1820. 40. WO 01/52885 41. Bjune et al (1991) Lancet 338 (8775) : 1093- 1096. 42. Fukasawa et al. (1999) Vaccine 17: 2951-2958. 43. Rosenqvist et al. (1998) Dev. Biol. Stand. 92: 323-333. 44. Costantino et al. (1992) Vaccine 10: 691-698. 45. WO 03/007985 46. Watson (2000) Pediatr Infect Dis J 19: 331-332. 47. Rubin (2000) Pediatr Clin North Am 4Ί: 269-285. BE2017 / 5163 48. Jedrzejas (2001) Microbiol Mol Biol Rev 65: 187-207. 49. Bell (2000) Pediatr Infect Dis J 19: 1187-1188. 50. Iwarson (1995) APMIS 103: 321-326. 51. Gerlich et al. (1990) Vaccine 8 Suppl: S63-68 & 79-80. 52. Hsu et al. (1999) Clin Liver Dis 3: 901-915. 53. Gustafsson et al. (1996) N. Engl. J. Med. 334: 349-355. 54. Rappuoli et al. (1991) TLBTECH 9: 232-238. 55. Vaccines (2004) eds. Plotkin & Orenstein. ISBN 0-7216-9688-0. 56. WO 02/02606 57. Kalman et al. (1999) Nature Genetics 21: 385- 389. 58. Read et al. (2000) Nucleic Acids Res 28: 1397- 406. 59. Shirai et al. (2000) J. Infect. Say. 181 (Suppl 3): S524- -S527. 60. WO 99/27105 61. WO 00/27994 62. WO 00/37494 63. WO 99/28475 64. Ross et al. (2001) Vaccine 19: 4135-4142. 65. Sutter et al. (2000) Pediatr Clin North Am 4Ί: 287-308. 66. Zimmerman & Spann (1999) Am Fam Physician 59: 113-118, 125-126. 67. Dreesen (1997) Vaccine 15 Suppl: S2-6. 68. MMWR Morb Mortal Wkly Rep 1998 Jan 16; 47 (1): 12, 19. BE2017 / 5163 69. McMichael (2000) Vaccine 19 Suppl 1: SlOl-107. 70. WO 02/34771 71. Dale (1999) Infect Dis Clin North Am 13: 22743, viii. 72. Ferretti et al. (2001) PNAS USA 98: 4658-4663. 73. Kuroda et al. (2001) Lancet 357 (9264): 12251240; see also pages 1218-1219. 74. Paoletti et al. (2001) Vaccine 19: 2118-2126. 75. WO 00/56365 76. Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th edition, ISBN: 0683306472. 77. Paoletti (2001) Vaccinated 19 (15-16) : 2118-26. 78. WO 03/009869 79. Almeida & Alpar (1996) J. Drug Targeting 3: 455-467. 80. Agarwal & Mishra (1999) Indian J Exp Biol 37: 6-16. 81. WO 00/53221 82. Jakobsen et al. (2002) Infect Immun 70: 1443- 1452. 83. Bergquist et al. (1998) APMIS 106 : 800-806. 84. Baudner et al. (2002) Infect Immun 70: 47854790. 85. Ugozzoli et al. (2002) J Infect Dis 186: 13581361. 86. Hennings et al. (2001) J Infect Dis. 183 (7): 1138-42. Epub March 1, 2001 87.Q Lin et al. (2001) J Infect Dis. 184 (8): 1022- O.88. Lin et al. (2004) J Infect Dis. 190 (5): 928- BE2017 / 5163 89. Glezen & Alpers (1999) Clin. Infect. Say. 28: 219-224 90. Madoff et al. (1994) J Clin Invest 94: 286-92. 91. Paoletti et al. (1994) Infect Immun 62: 32365 43. BE2017 / 5163
权利要求:
Claims (7) [1] 1. Conjugate comprising a fragment of a capsular polysaccharide (PSC) of a group B streptococcus (GBS) of serotype III and a support protein, in which the fragment is an oligosaccharide 5 comprising from 2 to 11 repeating units of the PSC of the GBS of serotype III and in which the conjugate has a degree of glycosylation from 2 to 9. [2] 2. Conjugate having the formula: (1) in which P represents a support protein, X represents either: (i) either BE2017 / 5163 (ϋ) 5 n 'is an integer from 1 to 10, n is an integer from 2 to 9 and in which n' is 1. [3] 3. Conjugate according to claim 1 or 2, in which the support protein is chosen from the group consisting of diphtheria toxoid, CRM197 and 10 tetanus toxoid. [4] 4. Conjugate according to claim 3, in which the oligosaccharide is a synthetic oligosaccharide. [5] 5. Conjugate according to claim 3, in which the oligosaccharide is prepared by depolymerization of 15 PSC of GBS serotype III. [6] 6. Composition comprising the conjugate according to any one of claims 1 to 5. [7] 7. The composition of claim 6, wherein said composition is a vaccine. 8. A composition according to any one of the preceding claims for use in a method for generating an immune response in a mammal. BE2017 / 5163
类似技术:
公开号 | 公开日 | 专利标题 AU2019208271B2|2021-11-18|Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof KR102157200B1|2020-09-21|Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof JP2020504760A|2020-02-13|Polypeptide antigen conjugates with unnatural amino acids US20180099039A1|2018-04-12|Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof EP3474890A1|2019-05-01|Pneumococcal polysaccharide-protein conjugate composition AU2015323651B2|2019-01-03|Vaccines against Streptococcus pneumoniae serotype 8 BE1024634B1|2018-05-14|IMMUNOGENIC COMPOSITIONS EP3274358B1|2020-09-16|Vaccine against carbapenem-resistantklebsiella pneumoniae AU2004228631B2|2010-12-02|Cholesterol-containing compounds and their use as immunogens against Borrelia burgdorferi JP6630440B2|2020-01-15|Synthetic vaccine against Streptococcus pneumoniae serotype 2 JP6622804B2|2019-12-18|Vaccine against Streptococcus pneumoniae serotype 4 KR20200106034A|2020-09-10|Vaccine against Klebsiella pneumoniae JP2021504438A|2021-02-15|Vaccine against Klebsiella pneumoniae
同族专利:
公开号 | 公开日 EP3439704A1|2019-02-13| BE1024634A1|2018-05-08| US20200405871A1|2020-12-31| WO2017175082A1|2017-10-12|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题 WO1991004335A1|1989-09-18|1991-04-04|Brigham And Women's Hospital|Enzymatic generation and recovery of group b streptococcus type iii capsular oligosaccharides| WO2009081276A2|2007-12-20|2009-07-02|Novartis Ag|Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom| WO2011121576A2|2010-04-01|2011-10-06|Novartis Ag|Immunogenic proteins and compositions| DE3841091A1|1988-12-07|1990-06-13|Behringwerke Ag|SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE| ES2055785T3|1989-01-17|1994-09-01|Eniricerche Spa|SYNTHETIC PEPTIDES AND THEIR USE AS UNIVERSAL VEHICLES FOR THE PREPARATION OF IMMUNOGENOUS CONJUGATES SUITABLE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.| KR920703114A|1989-07-14|1992-12-17|원본미기재|Cytokines and Hormone Carriers for Conjugate Vaccines| IT1237764B|1989-11-10|1993-06-17|Eniricerche Spa|SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.| SE466259B|1990-05-31|1992-01-20|Arne Forsgren|PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE| AT128628T|1990-08-13|1995-10-15|American Cyanamid Co|FIBER HEMAGGLUTININE BY BORDETELLA PERTUSSIS AS A CARRIER FOR CONJUGATED VACCINE.| IT1262896B|1992-03-06|1996-07-22|CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.| IL102687A|1992-07-30|1997-06-10|Yeda Res & Dev|Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them| IL117483A|1995-03-17|2008-03-20|Bernard Brodeur|Proteinase k resistant surface protein of neisseria meningitidis| HU9802199A3|1995-06-07|1999-07-28|Smithkline Beecham Biolog|Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein and use of| US6284884B1|1995-06-07|2001-09-04|North American Vaccine, Inc.|Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof| EP0977764A4|1997-03-26|2001-04-11|Brigham & Womens Hospital|Method for generating saccharide fragments| GB9713156D0|1997-06-20|1997-08-27|Microbiological Res Authority|Vaccines| WO1999024578A2|1997-11-06|1999-05-20|Chiron S.P.A.|Neisserial antigens| WO1999027105A2|1997-11-21|1999-06-03|Genset|Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection| KR100769103B1|1997-11-28|2007-10-23|세로노 제네틱스 인스티튜트 에스.에이.|Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection| CN1597694A|1998-01-14|2005-03-23|启龙股份公司|Meningococcal antigens| AU761780B2|1998-05-01|2003-06-12|Glaxosmithkline Biologicals Sa|Neisseria meningitidis antigens and compositions| NZ511540A|1998-10-09|2004-05-28|Chiron Corp|Neisseria genomic sequences and methods of their use| WO2000027994A2|1998-11-12|2000-05-18|The Regents Of The University Of California|Chlamydia pneumoniae genome sequence| WO2000033882A1|1998-12-04|2000-06-15|The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services|A vi-repa conjugate vaccine for immunization against salmonella typhi| GB9828000D0|1998-12-18|1999-02-10|Chiron Spa|Antigens| US6146902A|1998-12-29|2000-11-14|Aventis Pasteur, Inc.|Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions| EP1034792A1|1999-03-11|2000-09-13|Pasteur Merieux Serums Et Vaccins|Intranasal delivery of pneumococcal polysaccharide vaccines| KR100642044B1|1999-03-19|2006-11-10|글락소스미스클라인 바이오로지칼즈 에스.에이.|Vaccine| FR2791895B1|1999-03-23|2001-06-15|Pasteur Merieux Serums Vacc|USE OF TREHALOSE TO STABILIZE A LIQUID VACCINE| JP2002541808A|1999-04-09|2002-12-10|テクラブ，インコーポレイテッド|Recombinant toxin A protein carrier for polysaccharide conjugate vaccine| EP2281571A3|2000-01-17|2012-04-25|Novartis Vaccines and Diagnostics S.r.l.|Outer membrane vesicle vaccine comprising n. meningitidids serogroup b outer membrane proteins| GB0007432D0|2000-03-27|2000-05-17|Microbiological Res Authority|Proteins for use as carriers in conjugate vaccines| EP2166019A3|2000-07-03|2010-06-09|Novartis Vaccines and Diagnostics S.r.l.|Immunisation against Chlamydia Pneumoniae| NZ593617A|2000-10-27|2012-04-27|Novartis Vaccines & Diagnostic|Nucleic acids and proteins from streptococcus groups A & B| AU2002309706A1|2001-05-11|2002-11-25|Aventis Pasteur, Inc.|Novel meningitis conjugate vaccine| GB0115176D0|2001-06-20|2001-08-15|Chiron Spa|Capular polysaccharide solubilisation and combination vaccines| WO2003009869A1|2001-07-26|2003-02-06|Chiron Srl.|Vaccines comprising aluminium adjuvants and histidine| ES2317043T3|2003-06-23|2009-04-16|Baxter International Inc.|CARTE PROTEINS FOR VACCINES.| GB0502096D0|2005-02-01|2005-03-09|Chiron Srl|Purification of streptococcal capsular polysaccharide| GB0713880D0|2007-07-17|2007-08-29|Novartis Ag|Conjugate purification|GB201711274D0|2017-07-13|2017-08-30|Glaxosmithkline Biologicals Sa|Novel intermediates for the preperation of GBS polysaccharide antigens|
法律状态:
2018-07-19| FG| Patent granted|Effective date: 20180514 | 2019-12-13| MM| Lapsed because of non-payment of the annual fee|Effective date: 20190331 |
优先权:
[返回顶部]
申请号 | 申请日 | 专利标题 EP16020113.3|2016-04-05| EP16020113|2016-04-05| 相关专利
Sulfonates, polymers, resist compositions and patterning process
Washing machine
Washing machine
Device for fixture finishing and tension adjusting of membrane
Structure for Equipping Band in a Plane Cathode Ray Tube
Process for preparation of 7 alpha-carboxyl 9, 11-epoxy steroids and intermediates useful therein an
国家/地区
|